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I dedicate this work to my dear wife Carolin and my family  
  
  
  
 
 
 
“Seen in the light of evolution, biology is, perhaps, intellectually the most satisfying and 
inspiring science. Without that light it becomes a pile of sundry facts – some of them 
interesting or curious but making no meaningful picture as a whole.” 
T. Dobzhansky – “Nothing in Biology Makes Sense Except in the Light of Evolution” 
American Biology Teacher, 1973  
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Glossary 
Aneuploidy  Abnormal number of (parts of) chromosomes (Figure 13); absence of 
euploidy  
Array-comparative genomic 
hybridization  
A microarray-based high-resolution CGH method 
Chromoplexy  Rearrangements across several chromosomes 
Chromothripsis  The shattering of the genome in one catastrophic event 
Comparative genomic 
hybridization  
Conventional cytogenetic method for analyzing CNVs and SCNAs 
Copy number variation  Germline (normal) copy number variation in normal cells and tumor cells 
Diploid tumor  Tumor or tumor population that appears as a diploid peak in a DNA 
histogram 
Driver mutation  Mutation that confers a selective advantage 
log2-ratios  Logarithmic intensity ratio of tumor and control DNA in an aCGH 
experiment 
Loss of heterozygosity  Complete loss of one of the two parental alleles with or without (copy-
neutral LOH) a copy number change 
Next-generation sequencing  High-throughput sequencing technologies based on massively parallel DNA 
amplification and sequencing 
Oncogene  Gene that confers a selective advantage if hit by a gain-of-function 
mutation 
P/M divergence  Genetic divergence between primary-metastatic pairs 
Passenger mutation  A neutral mutation that does not confers a selective advantage 
Population  A group of cells (or nuclei) that form a peak in a DNA histogram 
Private mutation  A SNV or SCNA that is present in only one tumor lesion investigated for a 
given patient 
Purity  The relative proportion of tumor vs normal cells in a sample 
Shared mutation  A SNV or SCNA that is present in more than one but not all tumor lesions 
investigated for a given patient 
Single nucleotide polymorphism  Mutation that exists in the human population and is found in both tumor 
and normal tissue 
Single nucleotide variant  Mutation that occurred in the tumor, comprising also mutations detected 
by NGS 
Somatic copy number 
aberration  
Chromosomal aberration in the cancer genome of tumor cells 
Truncal mutation  A SNV or SCNA that is present in all tumor cells in a single tumor lesion 
Tumor suppressor gene  A gene that confers a selective advantage if hit by a loss-of-function 
mutation 
Tumorigenesis  The process of tumor development 
Ubiquitous mutation  A SNV or SCNA that is present in all tumor lesions investigated for a given 
patient 
Variant allele frequency  Fraction of alleles (in NGS data, reads) carrying a mutation 
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Summary 
Lung cancer is the most frequent cancer worldwide and is responsible for more death than any other 
tumor type. Genomic intratumor heterogeneity (ITH) is thought to be implicated in the resistance to 
current therapies, but in spite of its high prevalence, only a few studies have investigated genomic 
ITH in non-small cell lung cancer (NSCLC). Moreover, these studies have mainly focused on primary 
tumors. Yet, it is the progression to metastatic disease that makes lung cancer so lethal.  
We sought to shed light on the evolution of metastasizing lung adenocarcinoma (LUAD) by 
investigating the extent of genomic ITH in clonally related primary and metastatic sites in a cohort of 
16 LUAD patients. We established and validated the use of a refined multiparameter nuclei flow-
sorting approach and demonstrated that it substantially increases the purity of tumor DNA for 
subsequent genomic analyses. We applied this method to sort tumor populations from bulk tissues in 
order to determine somatic copy number aberrations (SCNAs) by array-comparative genomic 
hybridization (aCGH) and single nucleotide variants (SNVs) in 409 well-known cancer genes by 
targeted ultra-deep sequencing.  
This comprehensive genomic analysis revealed that 88% of SCNAs and 78% of SNVs were propagated 
from primary tumors to metastases, which indicated their accumulation in the primary tumors 
before metastatic dissemination. The fact that SCNAs were not increased at metastatic sites resulted 
in stable ploidies across our cohort even over long time periods. Despite the fact that the pure 
presence of SCNAs implies chromosomal instability (CIN) at some point during tumorigenesis, our 
data suggested that there is no or little increase in CIN during metastatic progression. Nevertheless, 
the analysis of shared and private alterations demonstrated a broad continuum from linear to 
parallel progression, indicating a late and early dissemination of metastases from their primary 
tumors, respectively. Furthermore, we confirmed that both primary tumors and metastases can be 
the source of further metastases. However, no recurrent alterations enriched in metastases were 
detected, which suggested that LUADs obtain their metastatic phenotype via additional mechanisms 
that were not investigated by this work, such as modification on an epigenetic and transcriptomic 
level in interaction with the tumor microenvironment and the immune system. 
Our data might have important clinical implications, because they indicate that most of the SCNAs 
and driver mutations can be detected in the primary tumor. However, the observation that 
established metastases spread to other sites in a cascading manner argues in favor of aggressive local 
treatment of all metastatic sites in patients with oligometastatic disease. 
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1. Introduction 
1.1 Importance of this work 
In the last years, genomic intratumor heterogeneity (ITH) in cancer has gained increasing attention, 
since its presence might challenge therapy decision making based on single biopsies. If a tumor 
consists of multiple clones that depend on different biological pathways because of individual 
mutations, resistance against (targeted) therapies might arise early because the treatment is not 
successful in eliminating all clones within a tumor. Additionally, if a single biopsy does not represent 
all of the existing clones and their mutations because of ITH, one or the other clone could be easily 
missed, because, despite being present in the tumor, it might not be present in a specific biopsy 
sample. This concept of genomic ITH and its impact on personalized medicine has recently been 
elaborated on by a landmark paper in renal cell carcinomas, which challenges therapy decision-
making based on single biopsies.1 Additionally, most cancer studies focus on genomic ITH in primary 
tumors only. However, it is its transformation to a metastatic disease that makes cancer so deadly, 
but studies of matched primary tumors and metastases are sparse.  
This is especially true for the data situation in non-small cell lung cancer (NSCLC). Only a small 
number of studies have investigated ITH between primary tumors and metastatic sites.2–4 Most of 
these studies have concentrated on exploring ITH of epidermal growth factor receptor (EGFR) 
mutations (reviewed in ref5) because they have direct clinical consequences. This is, because of the 
two most common mutated genes in NSCLCs, KRAS and EGFR, only mutations in EGFR are currently 
druggable. A recent NSCLC study makes aware that the extent to which genomic ITH is detected is 
attributable to differences in sequencing depth and to the presence of mixed (tumor and non-tumor) 
cell populations.6 These limitations have encouraged the design of this study, which aims 
technologically to establish a method for purification of tumor cell nuclei that are intermixed with 
normal cells. This study also aims biologically to infer the clonal relationship of primary lung 
adenocarcinomas (LUADs) and their metastases by investigating ITH of genomic alterations, such as 
copy number aberrations and cancer gene mutations, which allow quantifying the extent of 
chromosomal instability (CIN) over the course of metastatic disease.  
We believe that this study of temporally separated, matched lesions is better suited than one of 
unmatched material to studying CIN, because CIN describes a process of change, which has a 
temporal dimension by definition. 
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1.2 Lung cancer 
Lung cancer has the highest incidence and mortality rates of all cancers worldwide. It has been 
estimated that 1.8 million new cases were diagnosed and 1.6 million patients died from this disease 
in 2012 (Figure 1). Despite advances in earlier detection and improved treatment options, lung 
cancer is still the most frequently diagnosed cancer among males and the third most commonly 
diagnosed among females (after cancers of the breast and colon).7 Improving survival therefore 
remains a major challenge in lung cancer oncology, where 5-year survival rates are 17.7% across all 
stages and only 1% in metastatic disease (Table 1).8 One major reason for the high mortality rate of 
lung cancer is that the majority (70%) of patients are diagnosed with advanced stages or metastatic 
disease. Additionally, many patients with localized disease are often unsuitable for curative surgical 
treatments due to concomitant medical illness.9 
     
Figure 1 | Worldwide incidence and mortality of the top 20 cancers in 2012. Data retrieved from Globocan 2012 
(http://globocan.iarc.fr/).
7
 Lung cancer has the highest overall incidence and mortality rates, but in women alone, breast 
cancer is more frequent than lung cancer. 
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Table 1 | 5-year survival rates of NSCLC according to stage. These numbers are based on data from the National Cancer 
Institute’s Surveillance, Epidemiology, and End Results (SEER) database, based on people who were diagnosed with NSCLC 
between 1998 and 2000. For staging of NSCLC see Figure S1. 
 
 
 
1.2.1 Etiology and risk factors 
Tobacco smoking 
Cigarette smoking is considered by far the most important etiological risk factor for lung cancer.10 
The link between tobacco smoking and lung cancer was established by two landmark papers in 
1950.11,12 Both quantity and duration of smoking are known to correlate with an increased life-time 
risk for developing lung cancer.  
Awareness of the impact of tobacco smoke and improved screening methods have resulted in a 
decline in the incidence rate since the mid-1980s in men and since the mid-2000s in women in the 
USA. This gap in time between genders is attributed to historical differences in the timing of uptake 
and cessation. Death rates began declining in the USA with a delay of some years and decreased 
from 2007 to 2011 by 2.9% and 1.9% per year in men and women, respectively.13 In contrast, in other 
parts of the world, lung cancer-related incidences and deaths are on the rise.14 Even though pipe and 
cigar smoking is considered less dangerous by the public, the risk of developing lung cancer is 
comparable to that of light cigarette smoking.15,16 
 
Never smokers 
The term “never smoker” defines a person that has smoked less than 100 cigarettes in his or her 
lifetime.17 This includes lifetime non-smokers. Globally, it has been estimated that 25% of patients 
diagnosed with lung cancer are never smokers18, a value that underlies gender and geographic 
variations. Overall, 85% of lung cancers in men, but only half of all lung cancers in women, are 
related to smoking. Additionally, 60-80% of women that develop lung cancer in East and South Asia 
Stage 5-year survival rate 
IA 49% 
IB 45% 
IIA 30% 
IIB 31% 
IIIA 14% 
IIIB 5% 
IV 1% 
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are never smokers, compared to 15-20% in Europe and North America.19 Yet lung cancer in never 
smokers alone ranks in seventh place of leading causes of cancer death in the world and is 
responsible for more deaths every year than cervical, pancreatic, or prostate cancer.20 
 
Other risk factors 
Epidemiological studies have established an association between several environmental, genetic, 
hormonal and viral factors and the risk of developing lung cancer.21–31 Given the dominant role of 
tobacco smoking in lung cancer tumorigenesis, the association of passive smoking, also referred to as 
environmental tobacco smoke (ETS), with lung cancer risk has been widely studied. Environmental 
tobacco smoke comprises sidestream (released by cigarettes or other smoking devices) and 
mainstream (exhaled by smokers) smoke; it contains the same carcinogenic toxins – polycyclic 
aromatic hydrocarbons (PAHs), benzo[a]pyrene (BAP), and nicotine-derived nitrosamine ketones 
(NNK) – that are inhaled by smokers, although in lower concentrations.32 Nevertheless, metabolites 
of NNK have been detected in the urine of non-smokers exposed to ETS.33 Therefore, non-smokers 
exposed to ETS, for instance due to living with a smoker or working in a smoking environment, have a 
20-25% higher risk of developing lung cancer in their lifetimes. 32,34,35 Moreover, children raised in a 
smoker’s household have a threefold increased risk of developing lung cancer during adulthood.36  
Other risk factors, such as asbestos, ionizing radiation, air pollution, exposure to cooking fumes, and 
diet, all of which are unrelated to smoking, have been implicated.37–40 However, only weak 
associations have been established, resulting in the fact that major causes of lung cancer in never 
smokers have yet to be identified.  
Overall, the lifetime risk of developing lung cancer is 10-20 times higher in smokers than in never 
smokers and cigarette smoking accounts for 85-90% of all lung cancers in the Western world.41 
Consequently, in terms of prevention, the best strategy is to prevent the sequence of events that 
eventually lead to lung cancer. Therefore, efforts to prevent smoking and the initiation of smoking in 
children and teenagers in particular are important.17  
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1.3 Non-small cell lung cancer 
Non-small cell lung cancer accounts for 80-85% of all lung cancer cases.8,42 Based on its histology, 
NSCLC is divided into three major pathologic subtypes: LUAD, squamous cell carcinoma (LUSC), and 
large cell carcinoma. The most frequent subtype of NSCLC is LUAD, accounting for 40%, while LUSC 
and large cell carcinoma account for 25% and 15%, respectively.43 LUAD arises from distal airways, 
while LUSC is connected to the more proximal epithelium.44 
 
1.3.1 Connection to smoking 
All subtypes of NSCLC are associated with tobacco smoking, yet the strongest connection exists 
between smoking and LUSC.45 Conversely, LUAD is the most common form of lung cancer in never 
smokers.46 In addition to the global variation of the histopathological subtypes, there is a global trend 
of increasing rates of LUAD that co-occur with a decline in LUSC. This dominance of LUAD over LUSC 
has been hypothesized to be connected to the emergence of filtered cigarettes with low tar- and 
nicotine content that began to be produced once the detrimental effects of smoking were realized.47 
This change in cigarette design has presumably led smokers to inhale deeper to reach the same 
nicotine saturation as before.48 This could then result in a more peripheral distribution of tobacco 
smoke, prompting a shift from central LUSC to peripheral LUAD.47 Moreover, the decrease of PAHs, 
known LUSC inducers, has led to a concurrent increase in NKKs, which have been shown to promote 
LUAD.17 Together, this has resulted in a shift of the histopathological subtype rather than a decline in 
lung cancer rates. 
 
1.3.2 Cells of origin 
The airway epithelium consists of various cell types that vary in both their composition and 
proportion along the proximo-distal axis of the lung. The alveolar epithelium consists of type I and 
type II alveolar epithelial cells (AEC1 and AEC2, Figure 2).49 Although functional evidence is still 
lacking, different cell types are hypothesized to be the origin of the different histological subtypes of 
lung cancer. For instance, basal cells in the proximal airway are shown to serve as the cell of origin 
for LUSC.50 The evidence for LUAD is not that clear. In V-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS)-mutant mouse models, AEC2, clara cells, and putative bronchoalveolar stem cells 
are able to yield hyperplasia, yet only AEC2s have the capability to advance to malignant 
adenocarcinomas.51,52 This suggests that AEC2s might be the initiating cells for LUAD. 
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Figure 2 | Cells of origin and characteristic alterations according to histologic subtype. “Reproduced with permission from 
ref
50
, Copyright Massachusetts Medical Society. 
 
1.3.3 Molecular biology 
NSCLC is a heterogeneous disease, and despite the fact that some molecular alterations are shared 
among the histological subtypes, they markedly differ in the genes and therefore pathways affected 
by structural aberrations and mutations.  
 
Genomic landscape 
Whole-exome sequencing of smoking-related lung cancer has revealed a subtype independent mean 
somatic mutation rate of 8-10 mutations per megabase (106 base pairs).53–55 The mutational burden 
of the LUAD subtype of never smokers, however, is much lower (0.6-0.9 mutations per megabase).56 
Additionally, tumors from smokers are characterized by a high frequency of cytosine-adenine 
(C:G/A:T) transversion mutations (purine to pyrimidine or vice versa), a feature that is directly 
associated with tobacco exposure. On the other hand, cytosine-thymine (C:G/T:A) transition 
mutations (purine to purine or pyrimidine to pyrimidine) are predominant in lung cancers of never 
smokers.56 Further complexity ranges from the large number of somatic copy number aberrations 
(SCNAs) and gene rearrangements. This makes it extremely difficult to discover new genetic drivers 
among the background of a high burden of genetic alterations. It is estimated that approximately 
3,000 samples are needed to be able to detect genes that are significantly mutated in > 2% of lung 
cancers in smokers.57 
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Comparison of LUAD and LUSC 
Genomic analyses of tumors from NSCLC patients have revealed alterations that are common across 
different histological subtypes, yet the majority of genomic alterations are specific to one or the 
other subtype. A recent study, the most comprehensive of its kind, compares somatic genome 
alterations in LUAD and LUSC.58 It finds that only six genes – TP53, RB1, ARID1A, CDKN2A, PIK3CA, 
and NF1 – are significantly mutated in both tumor types, and of these, TP53, CDKN2A, and PIK3CA 
are more frequently mutated in LUSC (Figure 3a). On the level of SCNAs, only 11 focal amplifications 
are altered in both tumor types (Figure 3b), including amplifications of TERT, MDM2, MYC, CCND1, 
EGFR and ERBB2. Similarly, only 13 genes are focally deleted in both subtypes, with CDKN2A being 
the most significant one (Figure 3c). Interestingly, a comparison of significantly mutated genes in 
LUAD and LUSC compared to 19 other tumor types from the TCGA59 database has revealed that both 
NSCLC subtypes have a greater overlap with other tumor types than with each other.58 This indicates 
that the pathways and biological processes that are altered differ tremendously between these two 
subtypes.  
 
 
Figure 3 | Common and uncommon somatic alterations in LUAD and LUSC. Only genes that have been previously 
connected to lung cancer are included. Data were retrieved from ref
58
. 
 
Pathway alterations in LUAD 
A recent study that integrates data of whole-exome and transcriptome sequencing presents the most 
comprehensive map of alterations in LUAD. It reveals that in 76% of cases, genes of the RTK/RAS/RAF 
pathway are either mutated or otherwise altered. Other pathways that are affected are the PI(3)K-
mTOR pathway (25%) and the p53 pathway (63%). Further, alterations of cell cycle regulators (64%), 
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oxidative stress response pathways (22%), and mutations in various chromatin modulators and RNA 
splicing factors (49%) are frequently affected (Figure 4).53 Mutations in the oncogenes EGFR (11%) 
and KRAS (32%) result in a constitutive activation of the RTK/RAS/RAF pathway60,61 and are mutually 
exclusive with each other and with alterations in three other oncogenes of this pathway, namely ALK, 
BRAF and ERBB2.62,63  
 
Figure 4 | Pathway alterations in LUAD. Somatic alterations in key pathways that are dysregulated in LUAD are shown. 
Figure 4a from ref
53
: “Republished under the Creative Commons license (Attribution-Noncommercial) for non-
commerical/educational purposes from Nature Publishing Group. 
 
KRAS 
KRAS is in fact the most frequently mutated gene in LUAD and is more prevalent in smokers than 
never smokers.64 Like HRAS and NRAS, it encodes for a Guanosine-5'-triphosphatase (GTPase) that 
functions as a molecular switch regulating cell proliferation and survival. KRAS is normally tightly 
regulated between an inactive guanosine diphosphate (GDP)-bound state and an active GTP-bound 
conformation.65 The majority of mutations occur at codons 12, 13, and 61, so-called “hotspots”. 
Mutations at these conserved sites favor GTP binding and result in a constitutive activation of 
INTRODUCTION 
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mitogenic signaling.66–68 The most common KRAS mutation in LUAD is the G12C mutation that results 
from a C:G/A:T transversion mutation and is associated with exposure to tobacco smoke.69,70 Despite 
this high frequency of mutations, KRAS is currently not druggable, and strategies, such as blocking C-
terminal farnesylation, a post-translational modification that is required for protein activity, have 
failed in clinical trials to provide a statistically significant survival benefit.71,72 Other approaches, such 
as targeting the downstream effectors of KRAS, RAF and MEK, have been unsuccessful as well.  
 
EGFR 
The epidermal growth factor receptor (EGFR) is one of the four members of cell-surface receptor 
tyrosine kinases (RTK) that together constitute the epidermal growth factor (EGF) family. These 
regulate many developmental and metabolic processes. Like all members of this family, EGFR 
consists of an extracellular ligand-binding domain, a single hydrophobic transmembrane domain and 
an intracellular tyrosine kinase (TK) domain. Receptor activation is mediated upon ligand binding, 
which induces receptor dimerization and subsequent activation of the intrinsic TK.73 In cancer, TK 
activity can be activated by EGFR mutations, gene copy number amplification, and EGFR 
overexpression, all of which result in the promotion of cell survival, proliferation, invasion and 
metastasis. EGFR is overexpressed in many solid cancers, including stomach and colon cancers and in 
about 50-60% of NSCLCs.74–76 It is higher in LUSC than in LUAD and correlates with poor prognosis.77  
In contrast to KRAS, EGFR mutations are more frequent in LUAD in women, never smokers, and 
Asians, with widely varying frequencies across these populations.78–81 This is because the proportion 
of patients who are lifetime never smokers is higher among females and in Asian ethnicities.82 All 
mutations that are known to lead to a ligand-independent, constitutive TK activation are found in the 
first four exons (18-21) of the TK domain (Figure 5).83,84 The predominant single-point mutation is the 
EGFR L858R mutation in exon 21 and accounts for 43% of all EGFR TK mutations. Together with exon 
19 deletion mutations, EGFR L858R constitutes more than 90% of all EGFR activating mutations. 
Although the exact mechanisms are not fully understood, crystallographic analyses have suggested 
that these mutations confer a 50-fold increased TK activity by destabilizing the autoinhibited 
conformation that is normally formed in the absence of ligand binding in wild-type EGFR.84–88 
Mutations in EGFR have important clinical implications, since they can be exploited by targeted 
therapies.  
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Figure 5 | Schematic of EGFR mutations. Mutations in the four exons confer either resistance (exon 20) or sensitivity 
(exons 18,19, and 21) to small EGFR TKIs. The majority of mutations occur in exons 19 and 21. Note: the resistance mutation 
EGFR T790M has been implicated in a small proportion of untreated EGFR-mutated tumors.
89
 Adapted from 
https://www.mycancergenome.org/content/disease/lung-cancer/egfr/ 
 
 
1.4 Therapy of non-small cell lung cancer 
Surgery remains the standard treatment for stage I and II NSCLC, whereas chemotherapy is still the 
standard therapy for patients with advanced lung cancer. Despite the fact that histological 
heterogeneity in lung cancer was acknowledged as early as the 1950s,90 subtype-independent 
treatment decisions were continued until 2004. It was then recognized that specific mutations in 
EGFR are important predictive determinants for mediating sensitivity to gefitinib.75,91 Gefitinib, an 
EGFR small tyrosine kinase inhibitor (TKI), was initially approved in Japan and the USA for treatment 
of NSCLC as a result of the observation that EGFR is more abundantly expressed in tumor cells than in 
adjacent normal lung tissue.92 However, a consistent correlation between EGFR expression and 
response to gefitinib could not be detected.93 In 2008, it was recognized that tumor histology is an 
important determinant for response to chemotherapy. The combination of the two 
chemotherapeutics cisplatin and gemcitabine was found to be superior to cisplatin plus pemetrexed. 
However, this was true only for LUSC, because the survival among LUAD patients was better under 
treatment with cisplatin plus pemetrexed.94 Since then, dramatic improvements have been achieved 
in the outcomes of NSCLC patients, which can be attributed mainly to improvements in 
understanding NSCLC as a heterogeneous disease entity and efforts to classify NSCLC into subtypes 
based on both genotype and histology (Figure 6).  
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Figure 6 | Timeline depicting the historical milestones in the development of therapies for NSCLC. Until the 1990s, there 
was considerable pessimism about the treatment of NSCLC, and the benefit of chemotherapy for treating NSCLC was 
unclear. Treatment stratification by histology was not performed in these times. EGFR TKIs were initially approved as 
second-line therapy, as it was recognized that EGFR is overexpressed in NSCLC. In 2004, EGFR mutations were identified in 
patients who responded to first-generation EGFR TKIs, the beginning of the molecular era for personalized treatment of 
NSCLC. ALK-translocations were discovered in 2007, and 4 years later, the first drug was approved for the treatment of ALK-
rearranged NSCLC. First reports of the activity of immune-checkpoints inhibitors were reported in 2012 and the first anti-
PD-1 antibodies were approved in 2015. The EGFR T790M resistance mutation was reported as early as 2005, and after 
second-generation EGFR TKIs proved less effective than hoped at blocking T790M-mutant tumors, the first third-generation 
EGFR TKI against T790M was approved at the end of 2015 for second-line treatment in the USA, followed by EU approval 
for first-line treatment in early 2016. Recently, a second resistance mutation, EGFR C797S, was discovered, which confers 
resistance to third-generation EGFR TKIs. The first test to detect EGFR mutations in the blood of NSCLC patients was 
approved in June 2016 with the hope that consistent monitoring results in a benefit for metastatic EGFR mutation-positive 
NSCLC patients. Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Clinical Oncology, ref
95
, copyright 
2015, and updated. 
 
Targeted therapy and resistance 
LUAD can be considered a pioneer disease for personalized cancer medicine, because many 
treatment decisions today are based on the presence of predictive genomic alterations. Patients with 
EGFR mutations in exons 18, 19, and 21, for instance, are treated with small TKIs, such as gefitinib, 
erlotinib and afatinib. Stratifying patients according to mutations in EGFR helped increase response 
rates from 10% of unselected patients to approximately 75%.96 The inhibition results from a higher 
binding affinity of these small TKIs than adenosine triphosphate (ATP) and is so effective, because 
EGFR-mutant tumors depend on their aberrant EGFR signaling for survival.97,98 
The use of specific TKIs has also been studied for other molecular targets and impressive advances 
have been achieved. The small TKI crizotinib, for instance, was approved in 2011 for the treatment of 
anaplastic lymphoma kinase (ALK) rearranged NSCLCs. This was just 4 years after the fusion protein 
EML4-ALK – the result of a translocation between ALK and the echinoderm microtubule-associated 
protein 4 gene (EML4) – was identified in LUAD in 2007.99 
Despite initial responses to these targeted therapies, resistance ultimately develops. More than 50% 
of patients that are treated with EGFR inhibitors, for instance, eventually acquire a resistance via the 
secondary EGFR mutation T790M.100–102 It is believed that this mutation confers resistance either 
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through steric hindrance of EGFR TKIs or because it increases the affinity of EGFR for ATP.103,104 Drugs 
are therefore necessary to overcome this resistance mutation. Just recently, osimertinib (AZD9291), 
a new EGFR TKI, was found to be highly active in EGFR T790M mutated lung cancers.105 In fact, it 
received accelerated approval for the treatment of patients with EGFR T790M mutation-positive 
NSCLC in the USA, EU, and Japan just recently. However, an additional resistance mutation has 
already been identified. Interestingly, this mutation (EGFR C797S) is mutated at exactly the position, 
where osimertinib makes a covalent bond with EGFR, the cysteine residue 797.106 
Resistance mutations are thought to be already present in few cells of the tumor before the 
application of a targeted therapy and because of their low abundance they cannot be detected by 
current diagnostic tests. Indeed, a recent study in lung cancer cell lines has estimated that the EGFR 
T790M resistance mutation had pre-existed in approximately 0.6% of the parental population. The 
application of an EGFR targeted treatment resulted in the selection and outgrowth of cells with the 
T790M resistance mutation.107 Heterogeneity in a tumor due to the presence of different cell clones 
might be indeed a challenge for overcoming resistance in cancer therapies if clones with alterations 
that confer resistance to specific therapies exist prior to treatment. 
 
1.5 Intratumor heterogeneity 
Heterogeneity can be observed in many different ways both in tumor and normal tissue. This 
includes heterogeneity of phenotypes and cell morphology, gene expression, metabolism, motility, 
and angiogenic, immunogenic, and metastatic potential in tumors.108 The first observations of 
heterogeneity within cancers occurred as early as the mid-19th century and were of a phenotypic 
nature. In 1855, German pathologist Rudolf Virchow proposed that cancers arise from cells in mature 
tissues. He observed that cells in cancers differ in their cellular morphology. Despite now being 
considered the father of modern pathology, Virchow’s work was largely ignored in the 19th century 
and revived only toward the early and mid-20th century, when studies documented functional and 
genetic heterogeneity of tumors. It was shown that different cell populations with distinct 
cytogenetic profiles differ in their tumorigenicity in animal models.109 Further studies revealed that 
distinct subpopulations of cancer cells within tumors vary in their abilities to metastasize and in their 
resistance to treatment.110–112 
Although tumor development is regarded as a process of Darwinian evolution, with the 
understanding that selection forces act on populations of cells that differ in their heritable traits, the 
relative contributions of heritable (genomic) and non-heritable mechanisms are still not fully 
understood. Two mutually exclusive models have emerged to explain ITH: (i) the cancer stem cell 
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(CSC) model and (ii) the stochastic model (Figure 7). The CSC model assumes a hierarchical 
organization in which only a minor fraction of cells in a tumor is responsible for its progression and 
maintenance in a non-heritable fashion. This is because the ability to self-renew and differentiate 
into other non-stem cells is unique to CSCs. Therefore, CSCs are biologically distinct in that they have 
different intrinsic features than the bulk of other non-stem cells. This can be exploited to enrich 
tumor-initiating activity by sorting CSCs based on these intrinsic characteristics.113 Conversely, the 
stochastic model posits that a tumor is biologically homogeneous and random intrinsic or extrinsic 
factors result in the heterogeneous behaviors of the cancer cells, including tumor initiation capacity. 
Therefore, cell behavior cannot be predicted by intrinsic characteristics, and tumor-initiating activity 
cannot be enriched.114 The essential difference between these models is that phenotypic and genetic 
heterogeneity are irrelevant for tumor progression under the CSC model, as long as they do not 
affect the CSCs, because selection only acts on heritable phenotypes of CSCs. In contrast, genetic 
heterogeneity involves variation, and variation is necessary for selection under the stochastic model.  
The existence of CSCs has been demonstrated in hematopoietic malignancies115 and has been 
suggested with increasing evidence also in solid tumors.116 Still, it remains a subject of debate for 
many reports on solid tumors. This is because the CSC model requires, by definition, experimental 
evidence, such as tumor initiation at limited dilution. 117 Most of the data supporting the CSC model 
originate from mouse transplantation assays, which underestimate the number of cells in human 
tumors with tumorigenic potential due to variations in xenotransplantation conditions.118 In addition, 
in situations where many cells in a tumor have the ability to initiate tumors, which are then defined 
as CSCs, enriching for them becomes meaningless.  
 
Figure 7 | Two models of tumor growth. The stochastic model (a) results in tumor heterogeneity because all cells can self-
renew and differentiate, whereas in the CSC model (b) heterogeneity can only arise from CSCs. In both models, mutations 
can further contribute to ITH. Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer, ref
117
, 
copyright 2013. 
a    stochastic model b     CSC model 
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1.6 Tumor evolution 
Tumor evolution is loosely related to the concepts of evolutionary biology. The traditional so called 
“Darwinian” model of tumor evolution posits that selection plays a critical role in tumor development 
and that this results in multiple clonal expansion rounds, each of which is characterized by the 
acquisition of an additional mutational event that leads to a so-called “selective sweep” (Figure 
8a).119 Selection favors well-adapted clones over less well-adapted clones and thus allows them to 
produce more offspring. Over time, this results in clonal outgrowth and can ultimately lead to a 
situation where one clone dominates the entire tumor. Yet, this process can only occur if there is 
enough time for the selected clone to sweep through the tumor, i.e. enough time needs to pass for 
the next driver mutation to happen. Consequently, mutations and selection are inextricably linked 
with each other, but whereas mutations are considered to happen randomly, selection is a non-
random process.120 This depiction is based macroscopically on a single time point and therefore 
limited in reflecting tumor dynamics over time. Chromosomal instability (CIN) with ongoing 
alterations and mutations is likely to alter the selective pressures that are experienced by individual 
populations. Therefore, tumor evolution in the presence of CIN is probably non-linear on a 
microscopic scale, resulting in genetic heterogeneity due to coexisting tumor cell populations (Figure 
8b). 
 
Figure 8 | Schematic view of monoclonal and multiclonal models of tumor progression (a) Linear model of tumor 
progression where multiple clonal expansions driven by mutations in oncogenes and tumor suppressor genes eventually 
result in one dominant clone due to concomitant selection of the newly expanded clone. (b) Multiclonal model of tumor 
progression. Despite the fact that tumors are the product of one cell that initially experienced mutations, inherent 
chromosomal instability can allow for clonal diversity. Clone sizes can change during tumor evolution due to selection of 
clones with benefical mutations. This can lead to the extinction of clones, but also to the emergence of new clones over 
time. Note: this process of clonal diversity does not necessarily imply gradual processes, but can also result from 
punctuated events (see Figure 10). “Reprinted from ref
113
, copyright 2010, with permission of Elsevier”.  
a 
b 
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A central question in tumor evolution is how fast mutations appear that eventually lead to ITH with 
the presence of multiple clones within a neoplasm. Two theories have been proposed for this context 
and are valid only under the assumption that selection drives cancer evolution: gradualism and 
punctuation (Figure 10). Gradualism posits that tumor evolution derives from a constant 
accumulation of mutations with subsequent selective clonal outgrowth, whereas the punctuated 
theory proposes that tumor evolution happens in short time intervals of change followed by longer 
time periods of stasis.  
The punctuation theory of cancer evolution would hereby be analogous to the saltation theory of 
evolutionary biology. Saltation theory suggests that large phenotypic changes from one generation to 
the next are the result of sudden large-scale mutations, so-called “macromutations”.121 In other 
words, the genetic events themselves and not the phenotypic changes they cause are punctuated. 
This should not be confused with the evolutionary theory of punctuated equilibrium, which proposes 
that large phenotypic change results from rapid, but gradual genetic evolution in an isolated 
population (Figure 9a).122 Both saltation theory and punctuated equilibrium theory are in fact in 
concordance with Darwin's theory of evolution by natural selection. Richard Goldschmidt postulated 
his theory about macromutations in 1940 and was the first scientist to use the term “hopeful 
monsters”, which are the result of single macromutational events (Figure 9b).123 
 
Figure 9 | Punctuated equilibrium and hopeful monsters. (a) Gradual accumulation of mutations in small spatially isolated 
niches (here, an intestinal crypt). Only after a sufficient number of driver mutational events (orange, pink) are acquired a 
clonal expansion takes place (red). Despite the fact that mutations are acquired gradually, the evolution of the tumor 
appears punctuated from a macroscopic perspective. (b) A hopeful monster with a large change in phenotype is generated 
in a single cell division. Therefore, tumor formation is the result of a single catastrophic event. Reprinted by permission 
from John Wiley and Sons: Journal of Pathology, ref
122
, copyright 2016. 
a 
b 
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Recently, macromutations, punctuated changes in genotypes, have been assumed to occur during 
cancer evolution. Chromothripsis, for instance, describes the shattering and reassembly of focal 
regions deriving from one catastrophic event, and has been reported in many cancer types.124 
Chromoplexy on the other hand refers to the interweaving of multiple larger chromosomal regions 
involving multiple chromosomes, and was first identified in prostate cancer.125 Genome doubling, 
also referred to as “whole genome duplication (WGD)”, affects approximately 40-50% of solid 
cancers and can be viewed as another saltation theory, because it is believed to happen as a failure 
of a single mitotic event.126. A recent study has provided insights into the evolution of SCNAs during 
tumorigenesis by quantifying SCNAs of single cells in breast cancer.127 This study has assumed that 
changes of copy number alterations occur as punctuated events during breast cancer evolution, 
because, despite the fact that ITH of SCNAs was omnipresent, single cells with intermediate patterns 
of these SCNAs have not been detected. 
 
 
Figure 10 | Theories of tumor evolution implying the presence or absence of selection. Under selection, the aberrations 
that are present in a tumor at a single point in time can be the result of gradual changes or of single events that are not 
repeated. In contrast, neutral evolution occurs in the absence of selection and all cells grow at equal rates. Yet, in a drifting 
population, random effects can result in an increase or decrease of clone sizes. 
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Recent studies challenge, at least in part, that selection is a ubiquitous force during tumor evolution. 
In some tumors, the genetic diversity is orders of magnitudes higher than expected from a selection 
process as anticipated by the Darwinian model of tumor evolution.128 Likewise, a study of colorectal 
cancer provides evidence that tumors grow as a single clonal expansion, a so-called “Big Bang”, in 
which the clonal distribution is not determined by selection but by the point in time when the clone 
is generated, followed by neutral evolution.129 
These observations have resulted in the theory of neutral evolution in cancer development. Neutral 
evolution is defined as “the absence of clonal selection”130 and proposes that all cells grow at the 
same rate as one another. In a recent study across 14 different solid cancers131, 30% of tumors 
seemed to have evolved by neutral evolution, assuming that selection might be less widespread than 
perhaps expected from a gradualist evolutionary perspective. In this context, it is the timing of the 
occurrence of a new mutation rather than strong clonal selection for this mutation that predicts 
subclonal dynamics of a tumor. However, it has been noted that a neutrally evolved tumor 
dominated by a “lucky” clone, which just happens to grow faster due to random effects, is 
indistinguishable from a tumor that is the result of clonal selection.122 
 
1.7 Metastasis 
Historically, metastases were thought to be secondary neoplasms that arise independently from 
primary tumors and are therefore unrelated to them. Virchow himself proposed the idea that 
primary tumors infect the blood with so-called “tumor poisons” that eventually elicit metastatic cell 
growth at distant sites, a hypothesis that excluded the involvement of cells that disseminate from the 
primary tumor and travel to other sites of the body.132 We know now that metastases are the end 
result of a multistage process during which malignant cells spread from the primary tumor to other 
sites. This biological process is termed the “invasion-metastasis cascade” and comprises the following 
steps: cancer cell migration, local invasion, intravasation, survival in circulation, arrest at secondary 
sites, extravasation, micrometastasis formation, and metastatic colonization.133 So-called “circulating 
tumor cells” (CTCs) can be detected in the blood of the majority of carcinoma patients, including 
those who might never develop metastases.134 This obscures the fact, that the last steps of the 
metastatic cascade are extraordinarily inefficient (Figure 11). Overall, it has been estimated that 
fewer than 0.01% of all tumor cells that manage to reach the bloodstream eventually become visible 
as macroscopic metastases.135 However, assuming that a tumor of 1 cm3 in size consists of 109 cells, a 
therapy that destroys 99.9% still leaves 106 cells to proliferate and these provide a basis for cellular 
diversity. 
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Figure 11 | Inefficiency of the invasion-metastasis cascade. “Reprinted from ref
133
, copyright 2011, with permission of 
Elsevier”.  
 
It remains controversial whether all metastases originate from (different) clones of the primary 
tumor or if metastases have the potential to spread to other distant sites. Further, it is currently 
unknown at which moment during tumorigenesis a metastatic founder cell or clone disseminates 
from the primary tumor. The only time that can be measured is the relative time point of clinical 
detection compared to the primary tumor. Therefore, it is important to study tumors in context of 
their metastatic biology, because it is the metastatic disease that makes cancer so deadly. In fact, 
metastases account for > 90% of cancer mortality, while primary tumors can often be treated well 
with surgical resection or radiotherapy.136,137  
 
1.7.1 Two fundamental models of metastatic progression 
Metastasis is the absolute characteristic that distinguishes benign from malignant tumors.138 
However, a better understanding of the biological principles of when and how metastases arise is 
crucial to treat tumors that have spread to other sites of the body. Metastases can be detected 
either at the same time as – or at least shortly after – the primary tumor (synchronous) or several 
months or even years after the primary tumor (metachronous). Currently, there are no reliable 
methods to predict whether and when a specific tumor will relapse or seed metastases. In colorectal 
cancer, for instance, primary tumor characteristics such as size, stage, or grade are not significantly 
different between patients with synchronous or metachronous metastases.139 And metastasis is not a 
self-contained disease. It involves a variety of interactions with other cell types and host factors, and 
its fate is subject to the interaction of stromal and immunological components of the local and 
systemic environment.138,140  
Several conceptual frameworks have been proposed that aim to explain the behavior of a metastatic 
cancer during development. This includes the two major models of metastatic progression: (i) the 
linear and (ii) the parallel progression models.141 Both assume that the metastases are clonally 
related to the primary tumor, that is, they derive from a common ancestral cell. For a clonal 
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relationship to be detectable, some mutational events such as single nucleotide variants (SNVs) or 
SCNAs are required to be present in both the primary tumor and the metastases. 
The linear progression model  
The linear progression model (Figure 12a) reflects the traditional paradigm of how metastatic 
evolution occurs. It is called “linear” because it assumes that the metastatic capacity of cells from the 
primary tumor involves the accumulation of unidirectional events.142,143 Its central assumption is that 
cancer cells acquire mutations such as SNVs and SCNAs sequentially and that this eventually leads to 
genetically better-adapted cancer cells. This step-wise acquisition of mutations is accompanied by 
multiple clonal expansions that eventually lead to a clone capable of colonizing other organs, as 
postulated by the invasion-metastasis cascade. Because not all mutations are beneficial or provide a 
fitness advantage, the acquisition of mutations necessary for the metastasizing phenotype is 
considered to underlie a random process. Therefore, the chance of such mutations occurring 
increases with the number of cell divisions. According to the linear progression model, dissemination 
typically happens shortly before the metastasis is clinically detectable, and thus the genetic distance 
between the primary tumor and the metastasis is small. This means that a large number of mutations 
is shared between the primary tumor and the metastasis and that they were already present in their 
most recent common ancestor.144 
Connected to the linear progression model is the concept of “metastatic cascades”, which describes 
a situation in which metastases give rise to other metastases in a cascading manner (Figure 12a).141 In 
many solid tumors, metastases occur 2-3 years after the primary tumor has been detected, and 
because the linear progression model assumes short time intervals between metastatic 
dissemination and detection, the theory of metastatic cascades assumes a very high turnover of cells 
at the metastatic sites. Consequently, the genetic distance among metastases is lower than to their 
primary tumor, meaning that metastases are more closely related to each other than to the primary 
tumor.  
The parallel progression model 
In comparison to the linear progression model, the parallel progression model (Figure 12b) posits 
that the metastatic clone disseminates early during tumorigenesis.145 The primary tumor and the 
metastasis evolve in parallel, providing both enough time to accumulate substantial private 
mutations and alterations. The result is a high genetic divergence between the primary tumor and 
the metastases. In a situation with multiple metastases, this model assumes that all of the metastatic 
founder clones disseminate early during primary tumor growth, leading to large genetic differences 
among the metastases. This is in contrast to the model of metastatic cascades, which postulates a 
series of metastatic expansions that are seeded from other metastases in a relatively short time. 
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Genomic profiling of the primary tumor with the aim of providing targets for therapeutic 
interventions of metastatic sites is presumed to be largely ineffective under the parallel progression 
model, because the genetic alterations that are required for successful colonization at metastatic 
sites are thought to happen outside of the primary tumor.145 
 
   
Figure 12 | Overview of models of metastatic progression in human cancer. (a) The linear progression model and 
metastatic cascade. (b) The parallel progression model. Adapted by permission from Macmillan Publishers Ltd: Nature 
Reviews Clinical Oncology, ref
141
, copyright 2015. 
 
1.8 Aneuploidy and chromosomal instability 
1.8.1 Definition of ploidy 
DNA-ploidy refers to the DNA quantity in cells. Historically, ploidy was estimated by DNA cytometry 
methods such as flow cytometry and image-based cytometry (ICM). While ICM is considered superior 
to flow cytometry when working with formalin-fixed tissue samples146–148, flow cytometry remains 
the standard for high-throughput and sensitive multiparametric cell assessment of fresh or fresh-
frozen tissues. The possibility to couple flow cytometry with cell sorting allows for the investigation 
of specific cells of interest, which is particularly useful in the research setting. These methods 
quantify the DNA content on a single cell level based on a stoichiometric DNA staining, e.g. with the 
DNA-intercalating dye 4´,6-diamidino-2-phenylindole (DAPI), and report differences in the quantity of 
DNA with a DNA histogram. Cell populations possessing a characteristic DNA content become evident 
as peaks on this histogram. 
Tumors are classified as diploid, tetraploid or aneuploid. This has historical roots from a time when 
tumors were distinguished solely according to where their cell populations appeared on these DNA-
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ploidy histograms, irrespective of the presence or absence of structural or numerical chromosome 
aberrations or translocations (Figure 14). Biologically, however, the term “diploidy” describes the 
state where a nonreplicating cell nucleus contains a homologous set of chromosomes that is in 
number an integral multiple of the normal haploid number of a given species, without the presence 
of chromosomal aberrations, a state also referred to as euploidy.149 Aneuploidy therefore is the 
absence of euploidy (Figure 13). Yet, to be in line with the current scientific usage of the term 
“diploid tumor,” this thesis considers a tumor population to be “diploid” if it appears as a diploid 
peak in a DNA-ploidy histogram (Figure 14a). 
 
 
Figure 13 | Definition of euploidy and aneuploidy. Depending on the species and cell type, euploidy refers to a haploid 
(e.g. yeast), diploid (e.g. humans) or polyploid (e.g. plants) karyotype. They are balanced genomic states of euploid 
karyotypes. In contrast, aneuploidy is defined as the absence of euploidy and describes an unbalanced genomic state. 
Whole chromosomes can be lost (nullisomy or monosomy) or gained (disomy or trisomy). In addition, only parts of 
chromosomes can be lost, translocated or gained. High-grade aneuploidy describes a complex situation that often occurs in 
cancer, where whole chromosomes are deleted or amplified, as well as the presence of chromosomal rearrangements. N, 
ploidy increasing from left to right. Adapted by permission from John Wiley and Sons: EMBO Reports, ref
149
, copyright 2012. 
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Figure 14 | DNA-ploidy status assessed by DNA cytometry. Schematic examples of DNA-ploidy histograms obtained from 
tumors that would be reported as diploid (a), tetraploid (b), and aneuploid (c). The x-axis in each graph represents the DNA 
quantity that can be measured with DNA-intercalating dyes such as DAPI. The vertical lines show the scale of DNA-ploidy 
values (2n, 4n, and so on), where 2n represents the DNA-ploidy for nuclei of diploid cells in the G0/G1 phases of the cell 
cycle. Diploid, normal cells (blue) that are usually intermixed with the tumor cells (red) such as fibroblasts, lymphocytes or 
epithelial cells are used as a reference for the 2n value. (d) An example of a DNA content histogram in order to show the 
connection between DNA-ploidy and the different stages of the cell-cycle. Cells in the S-phase lie along a continuum 
between cells in G1-phase and cells in G2-phase. Cells in G2-phase have already completed DNA replication, but not mitosis 
(M). These DNA content histograms classify tumors as diploid, tetraploid or aneuploid solely based on their DNA content as 
compared to normal, diploid cells (2n). The presence of chromosomal alterations is only evident for an aneuploid DNA-
histogram. Yet, the terms “diploid” or “tetraploid” tumor do not imply the absence of such alterations, and are used as a 
consequence of historical tumor-ploidy estimations by DNA cytometry. Adapted by permission from Macmillan Publishers 
Ltd: Nature Reviews Clinical Oncology, ref
150
, copyright 2015. 
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1.8.2 Aneuploidy 
Aneuploidy was first mentioned in 1922 due to the lack of a term that describes “a chromosome 
number that is not a multiple of the base chromosome number….Aneuploidy refers to hyper and 
hypodiploid chromosome numbers.”151,152 Aneuploidy therefore describes a situation when a cell, 
often tumor cell, harbors an incorrect number of chromosomes.150 “Correct” in this context refers to 
the aforementioned state of euploidy. In diploid cells, tetraploidy occurs transiently in later stages of 
the mitotic cycle (G2- and M-phase), at a moment when the entire genome has been replicated but 
before the cell has divided. In humans with a diploid genome, persistent tetraploidy is embryonically 
lethal.153 However, polyploidy (integer multiples of 2n) occurs in a few cell types naturally, such as 
megakaryocytes, hepatocytes, and placental trophoblasts.150 
Normally, cellular DNA content is tightly controlled by the cell-cycle associated apparatus to prevent 
genomic aberrations, including polyploidy and aneuploidy.154 Aneuploidy eventually results from 
chromosome missegregation during mitosis. It has been proposed since the 1990s that aneuploidy 
leads to a destabilization of the genome, which results in an imbalance of the genes required for 
mitosis. The dysregulations of two surveillance mechanisms are important in this context. First, 
deficits in the spindle assembly checkpoint (SAC), the main regulator of chromosome segregation 
during mitosis, are known to result in numerical aneuploidy.155 This mitotic checkpoint tightly 
regulates the correct separation of sister chromatids during mitosis. Any defects caused by reduction 
or overexpression of proteins that are implicated in this regulation can lead to numerical aneuploidy. 
Second, inappropriate connections between kinetochores and spindle microtubules can result in 
lagging chromosomes and eventually in chromosome missegregation.156 
 
1.8.3 Chromosomal instability 
Chromosomal instability eventually results in aneuploid progeny.157 However, the presence of 
aneuploidy at a given moment does not necessarily indicate an ongoing contribution of CIN; 
aneuploidy can simply be the result of a single event that is not repeated. Therefore, CIN is better 
understood as an ongoing process of change. This is an important distinction, as highly aneuploid 
tumors do not inevitably have to be chromosomally unstable. Indeed, half of all human tumors have 
been shown to be karyotypically stable.158,159 This means that in order to identify CIN, it is necessary 
to study spatially or temporally separated tumors, either within the same tumor mass or by 
comparing primary tumors to their metastases. Both aneuploidy and CIN have been implicated as 
principal contributors to genetic heterogeneity between cancers but also within single tumor lesions. 
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1.8.4 Aneuploidy, chromosomal instability and cancer 
Aneuploidy has been associated with cancer for more than 100 years. German zoologist Theodor 
Boveri was the first to propose that abnormal chromosome numbers are implicated in cancer 
development, based on his observations that sea urchin eggs undergo abnormal mitotic divisions.160 
Since then, recurring non-random patterns of aneuploidy in cancer have been recognized, yet no 
general theory has emerged to explain them. That cellular aneuploidy indeed could be a driving force 
in tumorigenesis had only become evident in 2013, when it was shown that chromosomal 
imbalances due to aneuploidy likely result in haploinsufficiency of tumor suppressor genes (TSGs).161 
This is in contrast to the common “two-hit hypothesis,” which states that TSGs require two hits, first 
a mutation and then a loss of heterozygosity (LOH) due to loss of the wild-type allele in order to 
result in a phenotype with increased tumor incidence.162 Conversely, only one hit is needed under 
the assumption of haploinsufficiency, because wild-type protein levels might be not sufficient in 
executing their TSG function.  
Owing to the typically late-stage disease of lung cancer patients, aneuploidy is omnipresent in lung 
cancers. In addition, aneuploidy induced by CIN in a mutant KRAS-driven lung cancer mouse model 
has been recently implicated in relapse and recurrence. In this model, CIN is induced by the 
overexpression of the SAC protein MAD2, and the tumors that overexpress MAD2 and KRAS are 
larger, more aggressive than tumors that only overexpress KRAS, and relapse quickly.163,164 This 
indicates a role of CIN and/or aneuploidy in lung tumorigenesis that might by independent of KRAS, 
potentially due to an increased heterogeneity of karyotype formation. Although increased CIN can 
facilitate the emergence of advantageous karyotypes, it more likely has deleterious effects. A recent 
study has illustrated this bivalent nature of CIN: Interference with the SAC in a mouse model with 
increased incidence of lung and spleen tumors has resulted in increasing cell death. This indicates 
that for tumor formation and maintenance, the rate of CIN needs to be high enough to promote 
tumorigenesis, but not so high that it leads to cell death or tumor suppression.165,166 Therefore, 
depending on the dosage, CIN can both promote and inhibit tumorigenesis. 
 
1.8.5 Aneuploidy and patient prognosis 
Since it has been recognized that most advanced-stage cancers are aneuploid, efforts have been 
made to link aneuploidy to patient prognosis. Early attempts in the 1970s relied primarily on the 
quantification of DNA content of nuclei isolated from solid human tumors by flow cytometry.157 In 
fact, this was one of the first large-scale applications of flow cytometry.167 A correlation between the 
DNA-ploidy status of tumors and the clinical outcome for the patients was only obtained in large 
studies that allowed for stratification according to tumor stage.150 Since then, it has been shown in 
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breast168, colorectal carcinoma169, and other solid cancers150 that patients with diploid tumors have a 
general better prognosis than patients with aneuploid tumors. Similarly, NSCLC patients with diploid 
tumors benefit from a substantially lower risk of NSCLC-related death compared to patients with 
aneuploid tumors, as indicated by a meta-analysis of 35 DNA-ploidy studies in lung cancer that where 
published before the year 2000 and included a total of more than 4,000 patients.170 Nonetheless, 
ploidy measurements are not performed routinely anymore, because of overall discordant results 
due to the lack of stratification of mixed patient cohorts with tumors of all clinical stages. 
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2. Aims 
This thesis is divided into two parts. The first, Part A, aims to develop and establish a technology that 
allows for the enrichment and genetic characterization of tumor cell nuclei from bulk tumor tissues. 
The second, Part B, aims to apply this technology to the genomic characterization of spatial and 
temporal genomic ITH of LUADs. 
 
Part A: Develop and establish a multiparameter nuclei flow-sorting technology 
Part A establishes a technique that aims to separate nuclei of tumor cells from nuclei of normal cells, 
in order to increase the precision of genomic analysis techniques for tumor populations. Therefore, a 
previously applied nuclei flow-sorting technique is refined. This includes the addition of an 
immunostaining for a tumor marker in order to allow for the isolation of tumor nuclei from bulk 
tissues. This is especially important for diploid tumor nuclei that cannot be distinguished from normal 
nuclei by DNA-ploidy histograms alone. Validation is performed by array-comparative genomic 
hybridization (aCGH) and targeted next-generation sequencing (NGS). Array-CGH is used to quantify 
numerical and structural copy number alterations and NGS is performed to detect somatic 
mutations. This is demonstrated in both fresh-frozen tissues and formalin-fixed and paraffin-
embedded (FFPE) tissues of malignant melanomas and LUADs. 
 
Part B: Decipher the genomic intratumor heterogeneity between primary LUADs and matched 
metastases 
Part B aims to apply the technique established in Part A in order to investigate ITH between matched, 
longitudinal primary-metastatic tumors of a cohort of LUADs. This helps decipher the clonal 
relationship between primary tumors and metastases and therefore infer their evolution over time 
and space. From a technological viewpoint, it comprises a comprehensive genomic characterization 
of sorted tumor populations through genome-wide SCNA analysis and mutational analysis of 409 
cancer census genes. Array-CGH and targeted ultra-deep sequencing are applied, respectively.  
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3. Materials and Methods 
Patients and tissue samples  
Fresh-frozen tissues were obtained from the biobank and FFPE tissues from the archive of the 
Institute for Pathology of the University Hospital Basel (IfP). Multiple frozen and FFPE test tissues 
were obtained for establishing the multiparameter flow-sorting approach, including LUADs and 
malignant melanomas. For Part B of this thesis, patients were chosen based on the following 
inclusion criteria: i) histologically diagnosed LUAD, ii) availability of two or more fresh-frozen 
biopsies, and iii) tissue samples differing in time point or site. In addition, FFPE tissues of different 
sites were used if available. In total, 35 fresh-frozen and two FFPE tissues were investigated. All 
tumors were evaluated histopathologically by two experienced lung pathologists from the IfP (Prof. 
Lukas Bubendorf and Dr. Sasenija Savic Prince). This study was approved by the Ethics Committee of 
Northwestern and Central Switzerland with the approval number EKBB 31/12. 
 
Cell lines and cytospins 
The cell lines A375 (malignant melanoma), HCC78 (NSCLC, LUAD), and H522 (NSCLC, LUAD) were 
obtained as a courtesy of Rosemarie Chaffard from the IfP. All cell lines were cultured in standard 
RPMI medium (Corning GmbH HQ, Wiesbaden, Germany) supplemented with 10% fetal bovine 
serum and grown in a humidified incubator with 5% CO2 at 37°C. Cells were split by trypsinization 
every 3-4 days when they reached a confluency of 80-90%. Cytospins were made by spinning 50µL 
cell suspension in a Cytospin™ 4 Cytocentrifuge (Thermo Fisher Scientific, MA, USA) at 300 rpm for 2 
min, followed by immediate fixation of the cells in Delaunay fixative (50% [v/v] ethanol, 50% [v/v] 
acetone, 2mM trichloroacetic acid). 
 
Flow-sorting experiments 
Isolation of nuclei 
Nuclei were isolated according to published protocols.171,172 Briefly, fresh-frozen tumors were minced 
in ice-cold nuclei isolation medium (NIM) buffer (10 mM Tris-HCl [pH 7.4] buffer containing 146 mM 
NaCl, 22 mM MgCl2, 2 mM CaCl2, 10% (v/v) DMSO, 0.05% (w/v) BSA, and 0.1% (v/v) IGEPAL CA-630). 
The nuclei were pelleted in a cooled centrifuge (300 g, 3 min, 4°C). The nuclei pellet was washed 
three times and finally resuspended in ice-cold NIM buffer and stored on ice for the subsequent flow 
cytometric analysis up to 8 h or at -20°C for longer storage up to 6 months. 
For FFPE tissues, the isolation of nuclei was performed as previously described173,174, with minor 
modifications. Histological sections of 55 µm were deparaffinized in xylene and rehydrated in 
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subsequent washings of 100%, 95%, 70%, 50%, and 30% (v/v) ethanol. Antigen retrievals for both the 
thyroid transcription factor 1 (TTF1) and the Sry-related HMg-Box gene 10 (SOX10) were performed 
in citrate buffer (pH 6.0) in a heat block at 95°C for 30 min. Nuclei were obtained after digestion with 
Collagenase III (final: 50 units/mL in 0.1 mM CaCl2/Phosphate-buffered saline [PBS]) in a shaking heat 
block (16 h, 37°C, 1,000 rpm). After the nuclei were pelleted at 500 g for 5 min, they were 
resuspended in FACS buffer (PBS, pH 7.4 containing 1 mM EDTA, 1% (v/v) fetal calf serum [FCS], 0.1% 
(v/v) IGEPAL CA-630) to stop the digestion. After subsequent washings, isolated nuclei were stored in 
FACS buffer at 4°C for up to 1 week or at -20°C for up to 6 months.  
 
TTF1 and SOX10 as markers in flow cytometry 
SOX10 and TTF1 were used in combination with DAPI for setting up the staining protocols and 
procedures. SOX10 is a marker of neural crest origin and involved in the development of 
melanocytes. It is expressed in all stages, from neural crest stem cells to terminally differentiated 
melanocytes.175–177 Nuclear SOX10-expression is found in practically all melanomas175,178 and SOX10 
was shown to have the highest overall detection rate when compared to the microphthalmia-
associated transcription factor (MITF) and other pan-melanoma cocktails.179 TTF1 is a protein that is 
expressed in the thyroid, lung, and ventral forebrain.180 It is a marker of cellular lineage of the 
terminal respiratory unit and is routinely applied to differentiate LUAD from LUSC: 72% of all LUADs 
are TTF1-positive.181  
 
Multiparameter flow sorting and DNA-ploidy analysis 
Nuclei were stained with DAPI for DNA quantification and ploidy analysis. In addition to DAPI, SOX10 
was also used in test tissues of malignant melanoma to set up the protocol and optimize the 
conditions for nuclei staining and sorting. Uniform TTF1 or SOX10 expression was ascertained by 
immunohistochemistry on corresponding FFPE tissue sections and evaluated by experienced lung 
(Prof. Lukas Bubendorf, Dr. Spasenija Savic Prince) or melanoma (Prof. Kathrin Glatz) pathologists 
from the IfP. In the LUAD cohort (Part B), 10 of 16 patients (62.5%) had TTF1-positive tumors. TTF1 
was therefore used as a second parameter in 25 tumor manifestations of these 10 patients to 
distinguish tumor nuclei from stromal components.  
All centrifugation steps were performed at 300 g for 3 min in a cooled centrifuge (4°C). Stainings 
were executed in nuclear NIM buffer for nuclei from fresh-frozen tissues or in FACS buffer for nuclei 
derived from FFPE sections (for composition of buffers see the “Isolation of nuclei” section). Nuclei 
were stained with an anti-TTF1 antibody (clone SPT24, Novocastra™, Product: NCL-L-TTF1) or anti-
SOX10 antibody (Human/Rat SOX10 Antibody, Monoclonal Mouse IgG1 Clone# 20B7, R&D Systems, 
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Product: MAB2864) on ice for 4 h, washed twice and incubated for 30 min with an anti-mouse IgG-
Alexa 647 secondary antibody (F(ab')2-Goat anti-Mouse IgG (H+L) Secondary Antibody, Alexa Fluor® 
647 conjugate, Thermo Fisher, Product: A-21237). To verify the TTF1- and SOX10-specific stainings, 
an IgG1 isotype control was used as a primary antibody control (Mouse IgG1 Isotype Control, R&D 
Systems, Product: MAB002). Concentrations of primary and secondary antibodies were 5 µg/mL and 
2 µg/mL, respectively. Stained nuclei were filtered through a 40 µm mesh, and DAPI was added to a 
final concentration of 5 µg/mL at least 30 min before flow sorting was performed on a BD Influx™ cell 
sorter (Becton-Dickinson, San Jose, CA, USA). The instrument setup is displayed in Figure S2. A 
specific gating strategy was developed and applied as explained in the “Gating strategy of the 
multiparameter flow-sorting approach” section. Ploidy was calculated from the ratio of the 
geometric means of the DAPI intensity signal in the tumor population versus the respective non-
tumor population (diploid without SCNAs, or “flat genomes”). Flow cytometric analysis and 
visualisation was performed with FlowJo X version 10.0.7 (FlowJo LLC., Ashland, OR, USA). 
 
Gating strategy of the multiparameter flow-sorting approach 
Additionally, a specific gating strategy was applied for the enrichment of single (Figure 15b), intact 
nuclei (Figure 15c). In all cases, an isotype control antibody was used to control for the sensitivity and 
specificity of the primary antibody and to quantify the background fluorescence that results from 
non-specific cellular protein interactions (Figure 15e).  
In a representative example of a SOX10-positive melanoma in Figure 15 three peaks of different 
ploidy are visible from staining with DAPI alone (Figure 15c). DNA peaks can overlap, which results in 
cross-contamination if gating is performed in DNA-ploidy histograms because they are one-
parametric visualizations of the DNA content only. To minimize this contamination here, each peak 
was gated separately in a two-parameter scatter plot (Figure 15e). Additionally, this helped set the 
threshold for positive staining, as the background fluorescence differs among different ploidy peaks 
(Figure 15f-h). Compared to the control (Figure 15f), staining with the specific antibody (here: anti-
SOX10) was able to separate two populations from the diploid peak (Figure 15k), one positive and 
one negative for SOX10. The other two aneuploidy peaks were both positive for SOX10 (Figure 
15l,m). 
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Figure 15 | Gating strategy of the multiparameter nuclei flow-sorting approach. A multiploid SOX10-positive melanoma 
with a diploid and aneuploid tumor population is shown as a general example. For all cases, the initial population (a) was 
stained for DNA content with DAPI and gated for single events (b). Only intact nuclei (c) were further included. (d) The final 
nuclei population is displayed in a two-parameter scatter plot. This procedure was done for an isotype control (e-h) in order 
to evaluate background staining intensities of different ploidies (f-h). The same was performed for nuclei stained with an 
antibody against SOX10 (i-m). Due to different background intensities of the different ploidies, each peak was gated 
separately (i) to separate positive from negative events. The ploidy of a population was calculated from the ratio of the 
geometric means of the DAPI signal (x-axis, FL9 Area DAPI) in each gated population versus the diploid, marker negative 
population. This gating strategy and analysis was applied on all TTF1-positive LUADs and all SOX10-positive melanomas with 
either an anti-TTF1 antibody or an anti-SOX10 antibody, respectively. 
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DNA extraction and quantification 
Genomic DNA was extracted with the Maxwell® 16 FFPE Plus LEV DNA Purification Kit (Promega, 
AS1135, Madison, WI, USA) according to the manufacturer's protocol. Briefly, after sorting, the nuclei 
were pelleted in a cooled centrifuge (16.100 g, 30 min, 4°C). The nuclei pellet was resuspended in 
180 µL Incubation buffer and 20 µL Proteinase K and digested in a shaking heat block (56°C, 16 hours, 
500 rpm). After digestion, 400 µL Lysis buffer was added and heated to 80°C for 10 min. The 
Maxwell® 16 Instrument was used to extract DNA in 50-100 µL nuclease-free water. Double-stranded 
DNA (dsDNA) was quantified with the Qubit® dsDNA HS (High Sensitivity) Assay Kit (Invitrogen™), 
which was used according to the manufacturer's instructions. Typical DNA extractions from sorted 
nuclei reached quantities of 100-200 ng/100,000 nuclei, depending on the ploidy. 
 
Whole genome amplification 
DNA of sorted populations from fresh-frozen tissues was amplified with the illustra GenomiPhi V2 
DNA Amplification Kit (GE Healthcare Life Sciences,PA, USA). This whole genome amplification (WGA) 
is based on an isothermal multiple displacement DNA amplification with the Φ29 enzyme, a high-
fidelity DNA polymerase with proofreading (3’-5’ exonuclease) activity. Amplified DNA was used for 
both aCGH and NGS. DNA from sorted populations from FFPE tissues was not amplified, in order to 
reduce sequencing biases. Notably, three criteria were applied to optimize the quality of amplified 
DNA and to reduce potential amplification biases. First, amounts of 50-100 ng were used whenever 
possible and second, equal amounts of test and reference DNA (46XX, Promega, Product: G1521) 
were amplified as suggested previously.182 Last, amplification was performed only for 1 h, because 
shorter reaction times with Phi29 were shown to significantly decrease amplification biases.183  
The DNA from the sorted populations was SpeedVac™-ed to 1 µL and mixed with 9 µL Sample Buffer. 
The mixture was denatured at 95°C for 3 min and immediately cooled on ice for at least 5 min. A mix 
of 9 µL Reaction buffer and 1 µL of the enzyme was added to the sample. Amplification was 
performed at 30°C for 1 h in a thermocycler, followed by inactivation of the Φ29 enzyme at 75°C for 
10 min. High molecular weight DNA (average ≥ 10 kb) was assured by gel electrophoresis with the 
FlashGel™ DNA System (Lonza, Basel, Switzerland). Nuclease-free water was used as a negative 
control. Amplified DNA was diluted 1/10 in nuclease-free water and quantified with the Qubit® 
dsDNA HS Assay Kit (Invitrogen™). Amplifications resulted in a total DNA quantity of around 4.5-5.5 
µg (225-275ng/uL) and no DNA product in the negative water control. 
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Array-comparative genomic hybridization  
Note: The DNA of the sorted populations from FFPE tissues (n=2) was not amplified and not digested. 
For FFPE-DNA, 600 ng of unamplified reference DNA was digested as described below. Labelling, 
filtering and hybridization procedures were not different between DNA from fresh-frozen and FFPE 
tissues. 
 
Digestion of DNA from fresh-frozen tissues 
The amplified DNA of the sorted populations from fresh-frozen tissues was digested with DNaseI to 
reach a DNA smear from 100 to 1,000 bp. Therefore, 1 µg of both the amplified sample and 
reference DNA was diluted with nuclease-free water to a total volume of 7 µL and mixed with 1 µL of 
10x Reaction buffer (200mM TrisHCl [pH 7.5], 100 mM MgCl2, 10 mM CaCl2). A DNAseI dilution was 
prepared by combining 1.25 µL DNAseI (5,000 units/mL, Thermo Fisher, Cat#89835) and 500 µL 1x 
Reaction buffer. Two microliters of this DNAseI dilution were added to the amplified DNA to reach a 
total volume of 10 µL. DNA was digested in a thermo cycler for 15 to 18 min at 30°C, followed by 
DNAseI inactivation at 75°C for 10 min. Degraded DNA with a molecular weight of 100-1,000 bp was 
assured by gel electrophoresis with the FlashGel™ DNA System (Lonza, Basel, Switzerland). 
 
Labelling and filtering 
Digested test and reference DNA were labeled with Cy3-dUTP and Cy5-dUTP, respectively, using the 
BioPrime® Array-CGH Genomic Labeling System (Thermo Fisher Scientific, MA, USA). Therefore, 
degraded DNA was incubated with 2.5x Random Primers in a total volume of 40 µL at 95°C for 5 min, 
followed by the addition of 9 µL Labeling Master Mix (5 µL 10x dUTP, 1 µL Exo-Klenow, 3 µL Cy3-UTP 
or Cy5-dUTP). Labeling was performed in a thermo-cycler at 37°C and stopped after 2 h by the 
addition of 5 µL EDTA. Labeled DNA was filtered with Amicon Ultra 30K Filter Units (Millipore, Cat# 
UFC503096). To do so, labeled DNA was mixed with 450 µL TE-buffer (10 mM Tris-HCl, 1 mM EDTA, 
pH 8.0.) and centrifuged at 8,000g for 10 min, followed by one wash with 500 µL TE-buffer. Finally, 
the DNA was eluted, and successful labeling was verified by calculating the specific activity (>30) of 
each sample (pmol dye/µg DNA) using a Nanodrop for evaluation. 
 
Hybridization, washing and scanning 
Labeled test and reference DNA were pooled and adjusted to a volume of 39 µL with TE-buffer. 71 µL 
Hybridization Master Mix (5 µL Cot-1 DNA, 11 µL Agilent 10x Blocking Agent, 55 µL 2x Agilent 
Hybridization Buffer) were added to each test/reference sample and incubated at 98°C for 3 min, 
followed by another incubation at 37°C for 30 min. Subsequently, each sample was hybridized on 
MATERIALS AND METHODS 
37 
180K SurePrint G3 Human CGH Microarrays (Agilent Technologies, CA, USA) for 24 h at 67°C in a 
rotating hybridization chamber. All microarray slides were washed according to the manufacturer’s 
instructions and scanned with the Agilent 2565C DNA scanner. Images were analyzed with Agilent’s 
Feature Extraction v10.7 using default settings.  
 
Detection of somatic copy number aberrations 
Feature-extracted aCGH data were evaluated using Agilent’s CytoGenomics v3.0.1.1 software. 
Recentralization was performed by setting ploidy within +/- 0.5 of the prior ploidy estimate, as 
calculated from DNA-ploidy flow cytometry. Aberrations were called with the aberration detection 
algorithm ADM2 set to a threshold of 12.0, with Fuzzy Zero and GC-content (window size: 2 kb) 
correction. All aberrations were manually inspected and corrected before the aberration data table 
and raw probe log2-ratios were exported and further processed by a custom workflow programmed 
in the statistical computing software R version 3.2.3. This included the Bioconductor package 
“copynumber” version 3.4184 for visualization of the aCGH data as produced in the frequency plot in 
Figure 29 and the sample specific copy number plot in Figure 33. 
It is important to note that diploid populations with “flat genomes,” that is, with no aberrations 
present except of common copy number variants (CNVs), were considered to be of non-tumor origin 
(see 4.1.3). They were used as germline controls to identify both SCNAs in aCGH data and SNVs in 
sequencing analysis (see the “Next-generation sequencing” section in “Materials and Methods”). In 
cohort-wide analyses, each SCNA was considered only once per patient to exclude 
overrepresentation of ubiquitous or shared SCNAs present in patients with more than two tumors. 
 
Next-generation sequencing with the Ion Ampliseq™ Comprehensive Cancer 
Panel 
Library preparation and sequencing 
Sequencing was performed on all sorted populations, both tumor and non-tumor populations. The 
non-tumor populations were used as germline controls. For three patients, non-tumor tissue was 
available and utilized to validate the usage of the sorted non-tumor populations as germline controls 
in NGS analysis (see 4.1.3). Library preparation was carried out according to the manufacturer’s 
instructions185. The Ion Ampliseq™ Comprehensive Cancer Panel (CCP), which targets the exons of 
409 genes frequently mutated in cancer, was used for both fresh-frozen and FFPE populations. Most 
importantly, the CCP includes all genes that are well known to be mutated in LUADs (a list of the 
genes can be found in Table S1). Quality checks of the libraries were performed for both the 
expected library size (using Agilent’s High Sensitivity DNA Analysis Kit on a Bioanalyzer) and library 
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concentration (quantitative real-time PCR with the Ion Library Quantitation Kits). Sequencing was 
performed with the Ion PI™ Chips on the Ion Proton™ Sequencer with a mean coverage of 965x. 
 
Variant calling and filtering 
Sequence alignment to target regions from the hg19 genome was performed with the IonTorrent 
TorrentSuite™ software. Variant calling was performed with the Torrent Variant Caller 5.0 plugin 
from the TorrentSuite (Thermo Fisher Scientific, MA, USA) using low-stringency settings (Somatic – 
Proton – Low Stringency), as suggested by the manufacturer . Variants with a Phred-scored quality of 
≥ 50 and a strand bias < 0.95 were considered, but had to meet the following thresholds: minimum 
coverage ≥10, minimum variant allele coverage ≥ 5, minimum variant allele frequency (VAF) ≥ 4%, 
homopolymer ≤ 10, and common_signal_shift ≤ 0.2. A variant was then considered present, if the 
ratio 
𝑉𝐴𝐹(𝑡𝑢𝑚𝑜𝑟)
𝑉𝐴𝐹(𝑔𝑒𝑟𝑚𝑙𝑖𝑛𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
≥ 4 or if 𝑉𝐴𝐹(𝑔𝑒𝑟𝑚𝑙𝑖𝑛𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) = 0. We applied this last filtering step, 
due to the use of sorted non-tumor populations (diploid populations without SCNAs, or “flat 
genomes”) as germline controls. Minute amounts of tumor DNA are still present in these 
populations, which is inevitable in the flow-sorting process. Known hotspot mutations of KRAS and 
EGFR were always considered somatic. All variants were annotated using ANNOVAR186 and curated 
by manual inspection using the Integrated Genomics Viewer (IGV)187. 
 
Whole-exome sequencing with the IonAmpliseq™ Exome RDY Kit  
Library preparation and sequencing 
Whole-exome sequencing was performed for the four tumor populations of patient 42 (three tumor 
population in the primary tumor and one in the metastasis). The Ion Ampliseq™ Exome RDY Kit was 
used to prepare libraries following the manufacturer’s protocol.  
Quality checks were performed as described in the “Library preparation and sequencing” subsection 
of the “Next-generation sequencing” section of this chapter. Template preparation and chip loading 
was done with the Ion Torrent™ Ion Chef™. Sequencing was performed with the Ion PI™ Chips on the 
Ion Proton™ Sequencer with a mean coverage of 85x (range: 68.3 - 100.5x).  
 
Variant calling and filtering of whole exome sequenced tumors from patient 42  
We performed very stringent variant calling and filtering for the whole-exome sequencing data for 
patient 42, as our focus was to investigate the genomic relationships between the tumor 
populations. Therefore, a smaller number of high-confident and validated mutations were prioritized 
over a large number of mutations. Variant calling was performed with both the Torrent Variant Caller 
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5.0 plugin from the TorrentSuite and the “somatic”-tools from VarScan2 v2.3.9, as described below. 
To achieve a high stringency, the intersection (variants called by both algorithms) was used for 
further ultra-deep re-sequencing with an Ion Ampliseq™ custom validation panel. The intersection, 
rather than the union, of the two variant calling algorithms was used, as high-confidence variants 
were favored over the number of variants in respect to evolutionary analysis. 
 
Variant calling with the TorrentSuite 
Sequence alignment to target regions from the hg19 genome was performed with the Ion Torrent 
TorrentSuite™ software. Variant calling was performed with the Torrent Variant Caller 5.0 plugin 
from the TorrentSuite using low-stringency settings (Somatic – Proton – Low Stringency). The 
following thresholds were applied for filtering the variants identified by the Ion Torrent Variant 
Caller: Phred-scored based quality ≥ 50, strand bias < 0.90, coverage ≥ 10, variant allele coverage ≥ 5, 
VAF ≥ 4%, and common signal shift ≤ 0.2. Variants, which were not filtered out, were considered 
present if the ratio of 
𝑉𝐴𝐹(𝑡𝑢𝑚𝑜𝑟)
𝑉𝐴𝐹(𝑔𝑒𝑟𝑚𝑙𝑖𝑛𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
≥ 4 or if 𝑉𝐴𝐹(𝑔𝑒𝑟𝑚𝑙𝑖𝑛𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) = 0. 
 
Variant calling with VarScan2 
A second, separate variant calling was performed between tumor and matched germline using the 
“somatic” command from VarScan2 v2.3.9.188 The input for VarScan2 was the SAMtools189 mpileup 
output from the combined tumor/normal samples. The “somatic” command from VarScan2 was 
applied with default settings, except for the following: minimum coverage (--min-coverage-
normal/tumor 10) was set to 10 for both the tumor and the normal sample; the minimum variant 
frequency (--min-var-freq 0.04) was set to 4%; both tumor and normal purity (--normal/tumor-purity 
0.85) were applied with a value of 85%; and variants with >90% support on one strand only (--strand-
filter 1) and fewer than five supporting reads (--min-reads2 5) were filtered out.  
Finally, for the purpose of this analysis, small insertions and deletions were not evaluated. Variants 
that were called by both approaches (intersection of both Variant Caller and VarScan2) were further 
curated by manual inspection using the IGV187. The variants (n=112) meeting all these criteria were 
eventually used for further validation by ultra-deep re-sequencing (mean coverage 5,864x) with an 
Ion Ampliseq™ custom validation panel. All variants were annotated using ANNOVAR186. 
 
Ion Ampliseq™ custom validation panel for patient 42  
A total of 112 mutations were detected in the four tumor populations of patient 42 by whole-exome 
sequencing (see “Whole-exome sequencing with the IonAmpliseq™ Exome RDY Kit”). The presence 
or absence of all mutations was validated with an Ion Ampliseq™ custom panel. This panel was 
Dissertation Thomas Lorber 
40 
designed using the online designer (www.ampliseq.com). Multiplex PCRs were performed according 
to the manufacturer’s protocol. Barcoded libraries (read length: 400 bp) were constructed, and their 
quality was examined with both a Bioanalyzer for the expected size range and a qPCR to assess 
quantity. Template preparation and chip loading was done with the Ion Torrent™ Ion Chef™. Ultra-
deep sequencing was performed with Ion 316™ Chips v2 on the Ion Torrent™ Ion S5™ system with a 
mean depth of 5,864x (range 5,203-6,118x). 
In total, 16 mutations were either absent in all tumor regions or identified as germline variants 
(overall validation rate 85.7%). The mean sample specific validation rate was 90.4% (range 87.5%-
93.8%). The presence or absence of the mutations was ensured by two additional quality check: (i) 
sorting replicates (which comprise resorting of the primary tumor and metastasis, DNA extraction, 
and WGA) were subjected to re-sequencing with this custom panel and (ii) sequencing replicates (in 
duplicates), starting from the library preparation step with individual barcoding. Both were 
performed for further certainty of the VAFs of the detected mutations. The correlation of the VAFs of 
both the sorting and the sequencing replicates were assessed by linear regression analyses. Here, the 
mean squared correlation coefficient R2 was 0.93 (range 0.91-0.96, Figure S13) for inter-sort 
comparison and 0.93 (range 0.90-0.95, Figure S14) for intra-sort comparison, including all tumor 
populations from the primary tumor (n=3) and the metastasis (n=1).  
 
Categorization of mutations and copy number aberrations based on their 
presence in primary tumors and matched metastases 
Mutational events, both SCNAs and SNVs, were categorized as ubiquitous, shared, and private , 
according to their presence in the primary tumor and corresponding metastases. An SCNA or SNV 
was defined as “ubiquitous”, when it was present in all tumors investigated for a given patient, or as 
“private” otherwise. An exception was made for patients with more than one metastasis and for 
patient 42 with a multiploid primary tumor. Here, the definition “shared” was used if an SCNA or SNV 
was shared between at least two, but not all, sorted tumor populations. Therefore, “private” was 
used in these patients to describe the presence in only one tumor population. Non-synonymous SNVs 
and splice-site- or regulatory SNVs (generally named nonsilent) were distinguished from synonymous 
and intronic SNVs (also referred to as silent). A functional effect prediction was further applied to 
nonsilent mutations as described below. 
 
Functional effect prediction and classification of mutations  
Combined scoring of five functional protein prediction algorithms was applied to nonsilent SNVs in 
order to distinguish pathogenic SNVs from non-pathogenic SNVs. All identified nonsilent mutations 
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were classified into five categories, based on the functional predictors SIFT190, Polyphen2191, 
MutationTaster192, FATHMM193 and Provean194. Binary scoring of these predictors was performed, 
where 1 is a “deleterious” and 0 is a “non-deleterious” mutation.  
In order to evaluate the level of confidence (𝐶) of calling a mutation “pathogenic,” the predictions of 
all five predictor algorithms were weighted as follows:  
𝐶 =
1
𝑛
∑ 𝑋𝑖   ,   𝑋𝑖 =
𝑛
𝑖=1
{0,1} 
where 𝑛 is the number of predictors with available information for a specific mutation, and 𝑋𝑖  is the 
binary prediction of a predictor algorithm with 0 being a “benign”, and 1 being a “pathogenic” 
mutation. The impact of the mutation on the protein function was than divided into five categories, 
depending on the value of 𝐶: Category 1 “confidently deleterious” (𝐶 = 1), Category 2 “deleterious” 
(0.66 ≤ 𝐶  < 1), Category 3 “possibly deleterious” (0.5 ≤ 𝐶  < 0.66), Category 4 “possibly non-
deleterious” (0.2 ≤ 𝐶 < 0.5) and Category 5 “confidently non-deleterious” (𝐶 < 0.2). 
Mutations in Categories 1-3 as well as nonsense (stopgain/truncating), splice-site, and frameshift 
mutations were considered “pathogenic”. Additionally, mutations in Categories 4 and 5 were 
considered “pathogenic” if these were predicted to be “driver” alterations by CHASM195 (Lung-
Adenocarcinoma; available online under www.cravat.us/CRAVAT/) or considered “passengers” 
otherwise. A default threshold of p ≤ 0.05 (p-value [missense]) was set for CHASM cancer driver 
mutations. 
 
Mean pairwise genetic divergence 
The genetic divergence of primary tumors and metastases for each patient was the number of SCNAs 
and SNVs differing between two samples divided by the number of SCNAs and SNVs that were 
present in both, the latter of which were likely present in their most recent common ancestor. The 
mean pairwise divergence (𝐷) is defined as  
𝐷 =
2
𝑛(𝑛 − 1)
∑ 0
𝑛−1
𝑖=1
∑
𝑋𝑖,𝑗
𝑌𝑖,𝑗
𝑛
𝑗=𝑖+1
  
where 𝑛 is the number of samples in a patient, 𝑋𝑖,𝑗 is the number of SNVs and SCNAs private to 
either sample 𝑖 or 𝑗 but not present in both, and 𝑌𝑖,𝑗  is the number of SNVs and SCNAs present in 
both samples 𝑖 or 𝑗. The mean pairwise divergence was calculated by comparing the primary tumor 
with the first biopsied metastasis only. 
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Purity estimation and characterization of phylogenetic relationship for tumor  
populations of patient 42  
Purity estimation 
We used EXPANDS196 version 1.7.2 with default parameters to infer the purity of 39 tumor 
populations from primary and metastatic LUAD samples from 16 patients. The size of the largest 
clone detected is a direct indicator for purity.197 SNVs that could not be explained by a clone present 
in 10% or more of the sample, at a  ploidy o f  six or less, were excluded. The remaining detected 
SNVs and copy number segments were used to predict the number of clones that coexisted in each 
tumor sample, clone size, clone specific SNVs/SCNAs, and phylogenetic relations between clones. 
Yet, due to the overall low number of somatic SNVs in most cases, we used EXPANDS for purity 
estimations and not for subclonal detection. Purity estimations were available for 35 tumor 
populations, but unsuccessful for four samples due to insufficient numbers of SCNAs (n=2) or SNVs 
(n=2). 
 
Phylogenetic relationship analysis for tumor populations of patient 42  
Phylogenetic relationships among tumor populations in patient 42 were calculated using the 
neighbor-joining algorithm provided by the R-package “ape”. Hereby, pairwise distances between 
clones were calculated as the number of copy number segments for which both clones had the same 
copy number, divided by the total number of copy number segments for which both clones had 
available copy number information. EXPANDS analysis was performed by Karen Pereira and 
Stephanie Greer (Division of Oncology, Department of Medicine, Stanford University School of 
Medicine, USA). Phylogenetic analysis was performed by computational biologist Dr. Noemi Andor 
(Division of Oncology, Department of Medicine, Stanford University School of Medicine, USA). 
 
Immunohistochemistry 
Immunohistochemistry (IHC) was performed on FFPE tissue sections using the automated 
immunostainer Benchmark XT (Ventana, Tucson, AZ, USA) following the manufacturer’s guidelines. 
The IHC for TTF1 was performed to validate uniform staining in TTF1-positive tumors (10/16 patients, 
62.5%) before multiparameter flow sorting. TTF1 can be expressed by normal lung alveolar epithelial 
cells or in thyroid follicular cells, as was the case in the thyroid gland metastasis of patient 12 (Figure 
S3). This information was necessary to validate the non-tumor origin of those cells in sorts with a 
TTF1-positive population that carried no SCNAs (“flat genome”) as detected by aCGH. The IHC for 
p16, a protein encoded by CDKN2A, was performed on the primary tumor and metastasis of patient 
42. SOX10-IHC was performed to validate uniform staining in SOX10-positive malignant melanomas. 
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4. Results 
The results of this thesis are divided into two parts. The first part (Part A) introduces a refined nuclei 
sorting method that includes tumor marker-assisted flow cytometry to enrich tumor nuclei from bulk 
tissues, most importantly from diploid tumors. To establish the methodology, cell cultures and 
human tissues of two cancer types were used: malignant melanoma and LUAD. The second part (Part 
B) of this thesis presents data that were obtained by applying the method described in Part A to a 
comprehensive genomic characterization, comprising genome-wide copy number aberrations and 
deep-sequenced cancer gene mutations, of matched primary-metastatic LUADs from 16 patients. 
 
4.1 Results Part A: Establish a multiparameter flow-sorting approach for genomic 
characterization of tumor nuclei 
4.1.1 Cell lines staining experiment 
Cell lines were used to test the possibility of nuclei being immunostained for transcription factors in 
addition to DAPI, which is used for the quantification of DNA. Two transcription factors were 
investigated: SOX10, because it is expressed in virtually all melanomas, and TTF1, because 70% of 
LUADs are TTF1-positive. Furthermore, TTF1 is used to differentiate LUAD (TTF1-positive) from LUSC 
(TTF1-negative) in diagnostic routine. For this purpose, three cell lines were used: HCC78, an NSCLC 
(subtype: LUAD) cell line, that was previously tested to express TTF1198, A375, a malignant melanoma 
cell line that was used in other studies as a positive control for SOX10199; and H522, an NSCLC 
(subtype: LUAD) cell line that does not express TTF1200. 
In line with these data, we detected nuclear expression of TTF1 in HCC78 by IHC (Figure 16a). 
Similarly, the malignant melanoma cell line A375 expressed the transcription factor SOX10 in the 
nucleus (Figure 17a). H522 was negative for both TTF1 and SOX10 by IHC (Figure 16a and Figure 17a) 
and therefore used as a negative control for flow cytometry analyses. In agreement with IHC, nuclei 
extracted from HCC78 were positive for TTF1 in flow cytometry, whereas no TTF1 signal above the 
isotype control could be detected in H522 nuclei (Figure 16b), which is therefore considered TTF1-
negative. While isotype controls are used widely in flow cytometry to measure the maximum 
background noise, the best control is to mix positive and negative samples before staining with an 
antibody for a protein of interest. By doing so, we were able to separate TTF1-positive HCC78 nuclei 
from TTF1-negative H522 nuclei (Figure 16c). Similar results were obtained with A375 and H522 for 
SOX10. In agreement with IHC, A375 nuclei were SOX10 positive, whereas H522 nuclei were negative 
for SOX10 by flow cytometry (Figure 17c). Mixing nuclei of both cell lines before addition of the anti-
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SOX10 antibody resulted in the separation of SOX10-positive A375 nuclei and SOX10-negative H522 
nuclei (Figure 17d). 
 
Figure 16 | Multiparameter nuclei flow cytometry with TTF1 in cell lines HCC78 and H522. (a) IHC for TTF1 on cytospins 
from the cell lines H522 and HCC78, respectively. (b,c) Multiparameter flow cytometry of nuclei extracted from both cell 
lines and stained for DNA content with DAPI (x-axis) and TTF1 or control antibody (y-axis). Cell lines were either stained in 
separate tubes or mixed before the addition of the anti-TTF1 antibody. 
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Figure 17 | Multiparameter nuclei flow cytometry with SOX10 in cell lines A375 and H522. (a) IHC for SOX10 on cytospins 
from the cell lines H522 and A375, respectively. (b,c) Multiparameter flow cytometry of nuclei extracted from both cell lines 
and stained for DNA content with DAPI (x-axis) and SOX10 or control antibody (y-axis). Cell lines were either stained in 
separate tubes (c) or mixed (d) before the addition of the anti-SOX10 antibody. 
 
4.1.2 Multiparameter flow sorting enriches for tumor DNA of diploid tumors 
Detection of SCNAs and inference of absolute copy numbers is difficult because of the issues that 
arise from samples with low to medium tumor purity and assumptions of ploidy for computational 
deconvolution. This is especially true for diploid tumors, where tumor cells cannot be separated from 
diploid normal cells by ploidy alone. Therefore, we applied this multiparameter flow-sorting 
approach to nuclei derived from diploid tumors followed by detection of SCNAs by aCGH. As a proof 
of concept, four diploid tumors, two malignant melanomas, and two LUADs were used. The 
melanomas were stained for SOX10 and the LUADs for TTF1. 
In all four cases, a diploid, marker-positive (SOX10 or TTF1) population (2N+) and a diploid, marker-
negative (2N-) population was detected (Figure 18a,c,e,g). Array-CGH of the sorted populations 
revealed the presence of SCNAs in all 2N+ populations (Figure 18b,d,f,h). The second, smaller peaks 
were considered the proliferating fraction (cells in G2-phase) of the diploid tumors, based on three 
observations: (i) Their ploidy was approximately two times the ploidy of the 2N+ populations, (ii) they 
were in number much less than the 2N+ populations, and (iii) their aCGH-profiles were identical to 
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those of the 2N+ populations, without the presence of any additional private SCNAs. In contrast to 
the 2N+ populations, no SCNAs were detected in the 2N- populations, except of common CNVs and 
aberrations due to gender differences (chromosomes X, Y). These data suggest that the 2N- 
populations consist of nuclei of normal cells that are also present in tumors such as fibroblasts, 
lymphocytes and/or epithelial cells. 
 
Figure 18 | Application of the multiparameter nuclei flow-sorting approach on diploid tumors. Sorts of two malignant 
melanomas (a,c) with subsequent genome-wide copy number aberration analysis (b,d) of both the diploid, SOX10-positive 
and diploid, SOX10-negative sorted population. Sorts of two LUADs (e,g) and the aCGH profiles of diploid, TTF1-positive and 
diploid, TTF1-negative populations (f,h). In all cases, isotype controls were used to detect antibody-specific staining. 
Orange: diploid, marker-positive populations; grey: diploid, marker-negative populations. The red 0 next to the aCGH 
profiles indicates a log2-ratio of zero, which is identical to a copy number of two. Therefore, any aberration above this line 
is a chromosomal gain or amplification and any aberration below is a loss or deletion. Note: The populations indicated as G2 
consist of nuclei from proliferating tumor cells (light orange) or proliferating normal cells (light grey). Their aCGH profiles 
were identical to their non-proliferation counterparts and are therefore not shown to exclude redundancy. 
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4.1.3 Diploid populations with flat genomes are of non-tumor origin and can serve as germline 
controls in sequencing studies 
The presence of SCNAs in all the 2N+ populations in the previous experiment suggests a tumor origin. 
However, one must be cautious, if the protein of interest is not expressed by the tumor alone, but 
also by cells of non-tumor origin. TTF1, for instance, is a lineage marker of the terminal respirator 
unit181 and is therefore always expressed by normal AEC2 cells in the lung and by normal thyroid 
follicular cells.180 Hence, both tumor cells and normal cells might be TTF1-positive in a given LUAD or 
in a thyroid metastasis. 
To genomically validate such circumstances, we selected two cases. The first case was a TTF1-positive 
primary LUAD with co-occurring TTF1-positive, normal alveolar epithelial cells (Figure 19a). In 
agreement with IHC, the multiparameter flow sorting by DNA content and TTF1 demonstrated the 
presence of both diploid, TTF1-positive (2N TTF1+) and diploid, TTF1-negative (2N TTF1-) populations 
in the primary tumor (Figure 19b). The matched adrenal gland metastasis contained only TTF1-
positive tumor nuclei but no TTF1-positive normal nuclei as verified by both IHC and flow cytometry 
(Figure 19c,d). As expected from IHC analysis for both the primary tumor and the metastasis, no 
SCNAs were found in either the diploid, TTF1-positive or TTF1-negative populations (Figure 19e). In 
contrast, a large amount of copy number alterations were detected in the aneuploid TTF1-positive 
tumor populations (AN TTF1+) of both the primary tumor and the adrenal gland metastasis (Figure 
19e). A similar situation was found in a thyroid gland metastasis of a patient with a TTF1-negative 
LUAD (Figure S3). Here, a 2N TTF1+ population was also visible in the flow cytometry analysis (Figure 
S3b). Yet, these were normal, diploid thyroid follicular cells, as ascertained by IHC (Figure S3a) and 
the absence of SCNAs (Figure S3c). 
To assess whether these sorted diploid populations without SCNAs (2N SCNA-negative) can be used 
as substitutes for germline DNA as controls in NGS studies, we submitted them to sequencing of 409 
well-known cancer genes for three cases. DNA from non-tumor material for each patient served as 
germline control. As in the aCGH analysis for SCNAs, no SNVs were detected in the 2N SCNA-negative 
populations for all three patients (Figure 21, Figure S4, and Figure S5). Conversely, all aneuploid 
tumor populations had somatic mutations, some of them with VAFs close to 100%. Likewise, 
heterozygous single nucleotide polymorphisms (SNPs: germline mutations) were presented with 
VAFs around 50% in the 2N SCNA-negative populations and reached VAFs of 100% or were lost in the 
tumor populations, indicating of LOH due to the loss of the wild-type or mutant allele, respectively. 
To further assure the non-tumor origin of the 2N SCNA-negative populations, we analyzed their 
distribution pattern of VAFs of heterozygous SNPs. The VAFs of these SNPs clustered around 50% in 
the 2N SCNA-negative populations similarly to in the germline controls, whereas the tumor 
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populations were characterized by skewed VAF distributions, attributable to SCNAs in the respective 
loci. In addition, similar distribution patterns were obtained for the tumor populations no matter if 
the tumor-free control DNA or the DNA extracted from the sorted 2N SCNA-negative populations 
(representative case in Figure 20, other two patients not shown) was used. These data suggest not 
only that the 2N SCNA-negative populations are of non-tumor origin, but also that DNA from these 
populations can be used as germline controls in sequencing experiments. 
 
 
Figure 19 | Example of diploid, TTF1-positive normal cells. Nuclei flow sorting and aCGH analysis of an aneuploid, TTF1-
positive LUAD with diploid, TTF1-positive alveolar epithelial cells. IHC for TTF1 of the primary tumor (a) and metastasis (c). 
Multiparameter flow sorting of the primary tumor (b) and metastasis (d). (e) Genome-wide copy number plots from aCGH 
analysis of sorted populations. Grey, normal cells without any SCNAs; blue, aneuploid, TTF1-positive tumor population of 
the primary tumor; green, aneuploid, TTF1-positive tumor population of the metastasis. The red 0 next to the aCGH profiles 
indicates a log2-ratio of zero, which is equal to a copy number of two. Note: This is patient 44 from the LUAD cohort from 
Part B of this thesis. 
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Figure 20 | Distribution of VAFs of heterozygous germline SNPs. The VAFs of diploid, SCNA-negative populations from 
Figure 19 (primary 2N TTF1- and primary 2N TTF1+) are compared to a tumor-free control from the same patient. The VAFs 
of the aneuploid tumor populations of the primary tumor and the metastasis are included as well to demonstrate the 
skewed VAF distributions of a tumor (as a result of various copy number states of the mutated loci) in comparison to the 
VAFs of a non-tumor population. VAFs > 80% in the tumor populations indicate the presence of LOH. Note: These are data 
from patient 44 from the LUAD cohort from Part B of this thesis. 
 
 
Figure 21 | Comparison of mutations in DNA of sorted 2N SCNA-negative populations, tumor-free control DNA and tumor 
populations. SNVs and selected SNPs are included to strengthen the fact that both SNPs and SNVs with VAF > 80% can be 
detected in sorted tumor populations. 
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4.1.4 Diploid and aneuploid cells coexist in multiploid tumors 
To establish the multiparameter flow-sorting technology, we screened multiple human tumor 
samples, and in most cases the tumors consisted of only one tumor population. These were either 
solely diploid or aneuploid. However, in one LUAD (see Part B: 4.2.8) and three malignant 
melanomas, we found 2N marker-positive populations in otherwise aneuploid tumors (Figure 22a,b 
and Figure 23a). In contrast to the case described in 4.1.3, where the 2N marker-positive population 
was of non-tumor origin, all diploid, SOX10-positive (2N+) populations of these three multiploid 
malignant melanomas were characterized by multiple SCNAs (Figure 22c,d and Figure 23d). 
In all three cases, shared SCNAs provided evidence for a clonal relationship between the 2N+ and the 
aneuploid tumor (AN+) populations. Indeed, in the first case, we did not detect a single breakpoint 
that was private to either the 2N+ or the AN+ population. Nonetheless, all tumor populations of this 
tumor were characterized by the same pattern of multiple focal gains and losses on chromosome 9p, 
comprising a homozygous deletion of CDKN2A (Figure 22e).  
In contrast to this first case, private and shared SCNAs were present in the second and third tumor. 
This included a breakpoint on 12q21.1 that existed only in the 2N+ population (Figure 22f) of the 
second case. Additionally, two other SCNAs were either shared by the 2N+ and AN2+ populations 
(11q22.1) or by the two aneuploid tumor populations (5q21.1). Similarly, the 2N+ population of the 
third case was characterized by two SCNAs on 5q11 and 11q22 that were not present in the 
coexisting aneuploid tumor population (Figure 23e). 
 
4.1.5 Clonal evolution deciphered by multiparameter flow sorting 
The malignant melanoma of the above described third case was a relapse at the primary site (local 
relapse). We thought to investigate the clonal relationship of the diploid (2N+) and aneuploid (AN+) 
tumor populations in this relapse with two additional lesions that were available for this patient; a 
lymph node metastasis and a skin metastasis. In contrast to the local relapse, the metastatic lesions 
consisted of single tumor populations, and these were purely aneuploid, not diploid (Figure 23b,c). 
Array-CGH analysis revealed a relationship between the 2N+ population of the relapse and the lymph 
node metastasis: two SCNAs on 5q11 and 11q22 that were private to the 2N+ population of the local 
relapse were also present in the lymph node metastasis (Figure 23d,e). In addition, a heterozygous 
CNV on 11q12.1 remained heterozygous for the diploid tumor population of the relapse and the 
lymph node metastasis, but was completely lost (homozygous deletion) in both the AN+ population 
of the relapse and the skin metastasis (Figure 23e). Conversely, the SCNA on chr4q was absent in the 
lymph node metastasis, but present in all the other tumor populations (Figure 23e). The lymph node 
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metastasis carried in fact multiple focal amplifications scattered around chr4 (Figure 23e). To further 
investigate the relationship between all populations and to infer the clonal evolution in this tumor, 
we sequenced 28 genes (full list in Table S2) that are commonly mutated in melanoma, including 
BRAF, NRAS, TP53, and the recently reported ARID2201, GRIN2 A202, PREX2203, and RAC1204. 
 
 
Figure 22 | Multiparameter nuclei flow sorting of multiploid malignant melanomas. Flow cytometry (a,b) and genome-
wide copy number plots (c,d) of two cases. Selected chromosomal regions that revealed a relationship between the 
populations are enlarged for case 1 (e) or for case 2 (f). Red arrows hint towards genomic breakpoints that lead to SCNAs. 
The red lightning bolt (e) indicates the abundance of multiple deletions clustered on chr9p in case 1. Tumor populations 
designated as G2 (cell in G2-phase) had the same aCGH profiles as their counterparts in G1-phase and only one profile is 
therefore plotted. 
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Figure 23 | Multiparameter nuclei flow sorting of three tumor lesions of a melanoma patient. Flow sorting of the local 
relapse (a), the lymph node metastasis (b), and the skin metastasis (c). Genome-wide copy number plots of all sorted tumor 
populations (d) and enlarged regions of selection aberrations (e) that show private but also shared copy number 
aberrations. Red arrows hint towards genomic breakpoints that lead to copy number aberrations. The red lightning bolt (e) 
indicates the abundance of multiple amplifications scattered across chr4 in the lymph node metastasis. Tumor populations 
designated as G2 (cell in G2-phase) had the same aCGH profiles as their counterparts in G1-phase and only one profile is 
therefore plotted. 
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The diploid, SOX10-negative population (2N-) from the relapse did not have any SCNAs and was 
therefore used as the germline control for the detection of SNVs and as the reference for SNPs. 
Sixteen SNVs were found, of which 10 were missense or nonsense mutations (Figure 24a). This 
included ubiquitous mutations of TP53 (VAF: 93-100%) and the common melanoma driver mutation 
NRAS Q61R70 (VAF: 32-73%). Interestingly, the VAF of the NRAS mutation was the highest in the 
lymph node metastasis. NRAS is located on chr1 and copy number analysis of the NRAS locus did not 
detect the chromosomal break on chr1 for the lymph node metastasis as compared to the other 
three tumor populations of the local relapse and the skin metastasis. This indicates a different 
evolutionary event on chr1 for the lymph node metastasis which caused the observed increase of 
NRAS-mutant alleles.  
Another informative locus was chr9p. The 2N+ population of the local relapse had only one copy of 
this chromosomal region, whereas the aneuploid population of the relapse and the skin metastasis 
had two copies. The lymph node metastasis even possessed four copies of this locus (Figure 23e). 
This is of interest because this region contains the gene PTPRD, and one SNV and multiple 
heterozygous SNPs of PTPRD were detected in this tumor. PTPRD mutations had a VAF of 100% in all 
tumor populations but the lymph node metastasis. Here, the VAFs were around 50% for all the SNPs 
and the SNV (Figure 24a). Taken together, we proposed an evolution where most of the mutations, 
including PTPRD, happened early and some accumulated at a VAF of 100% due to LOH, as seen for 
ARID2 on chr12 and TP53 on chr17. Furthermore, exemplified by the PTPRD mutation and the CNV 
on 11q21.1, the combined copy number and mutation data suggest that a common precursor 
contained one mutated PTPRD allele and the heterozygous loss of 11q22-11q25. Following additional 
losses of whole chromosomes or chromosome parts, the aneuploid tumor populations might have 
eventually resulted from a WGD of either a cell from the diploid tumor population of the local 
relapse or a common diploid progenitor cell (Figure 24b), a hypothetical model that is in agreement 
with a branched evolution of the lymph node and the skin metastasis. 
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Figure 24 | Clonal evolution of a malignant melanoma. (a) List of mutations detected in all populations with a targeted 
melanoma panel. Note that all mutations except the PREX2 mutation are ubiquitous. This includes 13 SNVs with VAFs 
between 30% and 70% and four SNVs with VAFs close to 100%, which indicates LOH at the loci of these SNVs. In addition all 
detected germline SNPs are shown. Of interest in this context is the locus of PTPRD (bold) with one SNV and five SNPs. (b) 
Hypothetical model of the clonal evolution of this tumor exemplified based on the somatic PTPRD mutation and the LOH of 
chr11q (Figure 23), as revealed from a CNV at 11q12.1 and a SCNA at 11q22. Data are in agreement with the assumption 
that all aneuploid tumor populations evolved from diploid precursors due to WGDs.  
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4.2 Results Part B: Genome-wide copy number and mutational analysis in 
longitudinal biopsies of matched primary and metastatic lung adenocarcinomas 
using a multiparameter flow-sorting approach 
4.2.1 Overview of the project 
This project aimed to investigate temporal and spatial ITH between primary tumors and matched 
metastases to study clonal tumor evolution in LUAD. Patients were included if at least two 
longitudinal fresh-frozen LUAD biopsies were available in the biobank of the IfP, and one of these 
was the primary tumor. Nineteen patients met these inclusion criteria (Figure 25).  
 
 
Figure 25 | Overview of the project 
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Additional metastases were included, if available. TTF1 expression was validated on large sections of 
each tumor. TTF1-positive tumors (n=25, 58%) were detected in 11 patients (58%) and subjected to 
multiparameter flow sorting with DAPI for DNA content (ploidy) and TTF1 to enrich for tumor cells. 
Tumors without TTF1 expression (n=18, 42%) were found in eight patients (42%) and sorted with 
DAPI for ploidy only. The tumors of 3 of the 19 patients that were initially included did not share a 
single breakpoint or a single SNV in aCGH and NGS analysis, respectively (Figure S6). The suspected 
metastases of these three patients were therefore considered second primary tumors and were 
therefore removed from this study of clonally related primary-metastatic LUADs. The final cohort 
included 12 primary-metastasis duos, three primary-metastasis trios, and one patient with a primary 
tumor and three metastases. This entailed patients with brain (n=4), intrapulmonary (n=4), adrenal 
gland (n=3), kidney (n=1), and thyroid gland (n=1) metastases, and with pleural effusions (n=3). A 
graphical summary of the localization of the primary tumors and their clonally related metastases is 
provided in Figure S7. The detailed composition of the cohort, including clinical annotation, is 
summarized in Table 2. 
 
Table 2 | Characteristics of 16 patients with clonally related LUADs 
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4.2.2 Multiparameter flow sorting results in tumor DNA of high purity  
As recently demonstrated, the availability of high purity tumor samples is fundamental for not 
overestimating ITH in genomic studies.6 All tumor specimens (n=37) from the 16 patients of the final 
cohort were therefore subjected to flow sorting with DAPI for DNA content (n=12 tumors, 6 patients) 
or additionally with the lineage marker TTF1 (n=25 tumors, 10 patients, Figure 26). The resulting 39 
sorted tumor populations were genomically profiled by aCGH to determine genome-wide SCNAs and 
by deep sequencing of 409 cancer-relevant genes to detect SNVs (mean coverage 965x). As expected, 
diploid, TTF1-negative populations carried no SCNAs (Figure 28a). Similarly, diploid populations of 
tumors that were sorted by DNA content only did not have any SCNAs (data not shown). We 
confirmed the absence of SNVs in these diploid populations in three patients with matched non-
tumor tissue (see Results Part A 4.1.3 and Figure S5). Consequently, diploid populations without any 
SCNAs were considered to be of non-tumor origin and served as germline controls for the NGS 
analyses. 
 
Figure 26 | Workflow of the multiparameter flow-sorting approach and genomic characterization of the sorted tumor cell 
populations. This approach comprises the isolation of tumor nuclei from both fresh-frozen and FFPE tissues, followed by a 
multiparameter sort with DAPI for DNA content and TTF1 for tumor cells. Subsequently, DNA of sorted populations was 
extracted and subjected to WGA with Phi29, followed by detection of SCNAs and SNVs with aCGH and NGS, respectively. 
 
In four patients (25%), TTF1-positive tumor populations of diploid DNA content (2N±0.2) were 
detected. The tumors of all other patients were aneuploid (>2.2N, Table 2). Almost all tumors (97%) 
consisted of tumor cells of one single ploidy. Only the primary tumor of patient 42 showed more 
than one tumor population in the multiparameter flow cytometry analysis (Figure 38a). The 
application of this flow-sorting approach increased the mean tumor purity from 54% (range: 7-89%) 
of unsorted material to 92% (range: 79-99%) as evaluated by EXPANDS205 (Figure 27). This is of 
particular importance for the genomic characterization of biopsies with low tumor cell proportions 
and of diploid tumors (Figure 28). Indeed, by using this multiparameter sorting approach, we 
achieved a tumor cell content of up to 90% in these sorted diploid tumor populations.  
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Figure 27 | Purity estimation before and after sorting. (a) Box plots show the median, first quartile, third quartile, 
minimum, and maximum of purity before and after sorting. (b) The bar plot illustrates the increase in purity because of 
sorting per sample (n=35). Note: Four out of the 39 sorted tumor populations were excluded because EXPANDS could not 
predict purity due to a low number of SCNAs and SNVs. 
 
 
Figure 28 | Multiparameter nuclei flow sorting of diploid tumor or low purity tumors. The diploid tumor (a) was separated 
from diploid, normal nuclei by the addition of TTF1 (y-axis) as a second parameter extra to DAPI (DNA content, x-axis). 
Second, a tumor with low tumor cell content (c) was sorted and purity was increased from 7.4% to 95%. Diploid normal 
nuclei (grey) displayed no SCNAs except of gender-specific differences of X and Y chromosomes (b,d). The TTF1-positive 
populations carried distinct SCNAs (red). 
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4.2.3 Recurrent mutations and copy number aberrations 
Targeted sequencing 39 tumor populations identified 318 pathogenic mutations affecting 96 of the 
409 investigated genes. An overview of genes recurrently mutated or affected by SCNAs is displayed 
in Figure 30. The most common ubiquitous mutations were found in genes previously known to be 
mutated in LUAD.53,206 These includes KRAS in six patients (37.5%); TP53 in five patients (31.3%); 
EGFR, ATM, and STK11 in four patients (31.3%); and CSMD3, EPHA7, KEAP1, NF1, and NOTCH4 in 
three patients (18.8%). As expected, mutations with LOH were mainly detected in TSGs such as ATM, 
KEAP1, NF1, PTPRD, STK11, and TP53. As a matter of fact, ubiquitous mutations of KEAP1, STK11 and 
TP53 always occurred in the context of LOH. 
Recurrent copy number gains involved the chromosomal regions 1q, 5p, 7p, 8q, and both arms of 
chromosomes 12 and 14 (Figure 29). This was in line with previous data207 that mapped these regions 
to genes known to be amplified in LUAD, such as ARNT (1q21), TERT (5p15), EGFR (7p11), MYC 
(8q24), KRAS (12p12), NKX2-1, and FOXA1 (both 14q13). Chromosome 9p21 was the only recurrently 
deleted region, with both homozygous (7 patients|43.8%) and heterozygous deletions (4|25%). 
Homozygous deletions are of general interest, because they cause an irreversible loss of genes, 
therefore indicating TSG function. In addition to the genes located on chr9p21, we detected only 
seven additional genes with homozygous deletions: TP53, RB1, PTEN, DCN, THSD4, HS3ST4, and 
WWOX. Concordantly, all of them have previously reported tumor suppressor activity. 208–211 
 
 
Figure 29 | Overview of recurrent amplifications and deletions. (a) Six regions were amplified in >30% of the patients (1q, 
5p, 7p, 8q, chr12, chr14). Only one region (9p21) was recurrently (>30% of patients) deleted in this cohort. Gains, blue; 
losses, red. Note: To exclude over- or underrepresentation, because of different numbers of samples per patient, each 
aberration was counted only once per patient. 
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Figure 30 | Overview of genes recurrently affected by SNVs and SCNAs. Overall, a high proportion of SNVs and SCNAs 
were ubiquitously affected in all samples of individual patients. Many TSGs (TP53, ATM, STK11, PTPRD) were mutated with 
the complete loss of the wild-type allele. Of note, KEAP1 was mutated in three patients, was always ubiquitous, and 
occurred in the context of LOH in all samples. 
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4.2.4 Stable ploidy and high concordance of copy number aberrations and cancer gene mutations 
Flow cytometry revealed that the ploidy of individual tumors was stable over time regardless of the 
time interval between the primary tumor and occurrence of the metastasis (Figure 31, p=0.89, 
Wilcoxon signed-rank test). Likewise, the metastasis of patient 49 remained diploid, despite the fact 
that it emerged 12.7 years after the detection of the diploid primary tumor. A high ploidy was 
associated with a short time until emergence of the metastatic tumors (p<0.05, univariate cox 
analysis, data not shown) and correlated with the total amount of SCNAs (r=0.79, p<0.001, Figure 
32a). Moreover, tumors with biallelic inactivation of TP53 or ATM had a higher burden of SCNAs 
(p=0.003, Wilcoxon signed-rank test) and higher ploidy (p=0.001, Wilcoxon signed-rank test) than the 
rest of the cohort. Of note, all diploid tumors were negative for TP53 or ATM mutations and also had 
the lowest numbers of SCNAs. 
 
 
Figure 31 | Ploidy of tumors per patient. Ploidy of individual tumors did not change significantly (p=0.89, Wilcoxon signed-
rank test), over time as calculated for the time interval between primary tumor detection and the emergence of the first 
metastasis (Δtime P -> M1). P, primary tumor; M1-3, first, second, third metastasis. Note: Patient 42 had a multiploid 
primary tumor and is excluded from this analysis. 
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Figure 32 | Scatter plot of ploidy and SCNA count (a) and Circos plot of the percentage of genome affected by SCNAs (b). 
(a) Ploidy correlated significantly (linear regression, r=0.79, p<0.001) with the burden of SCNAs. The number of SCNAs 
therefore increases with the ploidy of the tumor. (b) Circos plot showing the relative amount of the genome that is affected 
by SCNAs per sample. 
 
An overview of the SCNAs on a per-sample basis is depicted in Figure 33. Tumors from one patient 
were more similar to each other than to the tumors of other patients, as evaluated by hierarchical 
clustering of Euclidean distances based on SCNAs (Figure S8). One exception was the diploid primary 
tumor population (2.1N) of patient 42, which clustered together with the diploid tumor populations 
of the other three patients with diploid tumors probably due to the overall large number of copy 
number neutral regions (percentage of genome unaffected by SCNAs) of all diploid tumors in this 
cohort (Figure 32b).  
 
Figure 33 | Overview of genome-wide SCNAs per tumor population. Sex chromosomes were excluded. Red, loss; blue, 
gain; white, copy number neutral. P: primary tumor, M1-3: metastases. 
 
  
a                                                         b 
RESULTS 
63 
No significant difference in the number of additional non-ubiquitous (private and shared) mutational 
events (SCNAs and SNVs) were detected in the primary tumors or the metastases (median 12.8 vs. 
13.6 non-ubiquitous events per tumor, respectively; p=0.83, Wilcoxon signed-rank test), regardless 
that the time between primary and metastatic tumor detection was different in each patient (Figure 
34a). Most importantly, 80% of all detected SCNAs were ubiquitously present in the primary tumor 
and metastases (Figure 34b). Moreover, 88% (range: 68%-100%) of SCNAs were passed from the 
primary tumor on to the metastases. Likewise, 87% (range: 57%-100%) of SCNAs detected in the 
metastases were shared with the primary tumor.  
 
 
Figure 34 | Relative proportion of SCNAs and SNVs per sample and patient. (a) Proportion of non-ubiquitous (private and 
shared SNVs and SCNAs) per sample and patient. Metastases did not have higher amounts (p=0.83, Wilcoxon signed-rank 
test) of non-ubiquitous SCNAs and SNVs than primary tumors. (b) Circos plot showing the relative proportion of SCNAs per 
category (ubiquitous, primary only, metastasis/es only) per patient. P, primary tumor; M1-3, metastases. 
 
Similar concordance rates were found for SNVs. Here, 78% (range: 50%-100%) of mutations in the 
primary tumor were propagated to the metastases, and 73% (range: 33%-100%) of SNVs in the 
metastases were shared with the primary tumor. The VAFs of these ubiquitous mutations were 
significantly higher than of mutations that were private to only the primary or metastatic tumor 
(Figure S9; Figure S12). Most importantly, 86.3% of all pathogenic mutations in the top 11 mutated 
genes (TP53, KRAS, ATM, CSMD3, EGFR, STK11, NF1, LRP1B, KEAP1, NOTCH4 and EPHA7) were 
ubiquitous. This value was increased to 93.3%, if only mutations with VAF > 20% were considered. 
Yet, one mutation in TP53 (patient 49, VAF: 14%) and NF1 (patient 46, VAF: 49%), and two mutations 
in LRP1B (both patient 12, both VAFs of 33%), each private to the primary tumors were not 
propagated to their metastases (Figure 30). For EGFR, we detected two mutations that occurred in 
primary tumors only. One was an exon 21 mutation (H850Y) with a VAF of 4% in patient 31 who 
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already had the common EGFR driver mutation L858R (VAF: 63%). A double-mutation of EGFR H850Y 
with another exon 21 mutation has been recently reported212, but its effect on EGFR protein function 
is unknown. Another private EGFR mutation occurred in patient 48. This mutation (EGFR D379N, VAF: 
6%) occurred in exon 10 and is of unknown significance. 
 
4.2.5 High concordance of absolute copy numbers results in stable VAFs of ubiquitous mutations 
Next, the distribution of the VAFs and their change over time in primary tumors and their first 
biopsied metastases was investigated. Interestingly, VAFs of ubiquitous mutations remained largely 
unchanged (r=0.93, p<0.001, linear regression) between primary tumors and metastases (Figure 
35a), irrespective of the differences in time intervals between the tissue resections per patient 
(Figure S10). The same was true for absolute copy numbers (Figure S11). Furthermore, this resulted 
in a density distribution pattern of VAFs and copy numbers that indicated a truncal origin for 
ubiquitous mutations (Figure 35b; Figure S12). For instance, the majority of mutations with a copy 
number of three clustered around VAFs of 33% or 66%, indicating the presence of one or two 
mutated alleles, respectively. Similarly, mutations with a copy number of four displayed a high 
density at VAFs around 25% and 50%. Overall, 94% of mutations with a VAF ≤ 10%, a value indicating 
subclonality, were not spread to the metastases. Conversely, 92% of mutations with VAF ≥ 50% in the 
primary tumors and 97% of mutations with VAF ≥ 50% in the metastases were ubiquitously present 
in all biopsies, further supporting their truncal nature. 
 
Figure 35 | VAFs and copy numbers of ubiquitous mutations. (a) Scatter plot of the VAFs of ubiquitous mutations in 
primary tumors (P, x-axis) versus the first biopsied metastasis (M1, y-axis) revealed a significant correlation (linear 
regression, r=0.93, p<0.001). (b) Density plot of the absolute copy number (x-axis) and VAF (y-axis) of ubiquitous mutations, 
indicating their truncal origin. 
RESULTS 
65 
4.2.6 Genetic divergence between primary tumors and metastases reveals two patterns of 
evolution  
Metastatic dissemination follows the two general models of “linear progression” or “parallel 
progression”, which are based on the relative timing of emergence and genetic divergence between 
the primary tumor and its metastases.144 The mean pairwise divergence (D)213 is a measurement of 
the genetic divergence between primary/metastatic (termed P/M divergence) pairs. A broad 
continuum of these two progression models was detected in this cohort (Figure 36). The P/M 
divergence ranged from 0.03-0.51. At the lower end of this distribution was the rather linear 
progressing tumor of patient 41. Here, 97% of all SCNAs and SNVs were present in both the primary 
tumor and the brain metastasis. The highest P/M divergence was detected in patient 49 with a 
contralateral pleural effusion that had emerged 12.7 years after the detection of the primary tumor. 
Both shared only 49% of all SCNAs and SNVs, indicating a parallel progression. The median time 
interval between primary tumor detection and the first biopsied metastasis was 10.7 months. 
Removing patient 49 as an outlier from the analysis lead to the result that the genetic P/M 
divergence did not correlate with the relative timing to metastasis (r=0.2, p=0.42). Notably, tumors 
with TP53 or ATM mutations displayed a low P/M divergence and a tendency toward early 
emergence of metastases. However, these were only significant (p=0.042 for P/M divergence and 
p=0.006 for time to first metastasis, Wilcoxon signed-rank tests) for tumors with biallelic inactivation 
of TP53 or ATM. 
 
4.2.7 Two patterns of metastatic spread 
Multiple, spatially separated metastases were available for four patients (patients 20, 22, 31 and 36). 
To investigate the directionality of metastatic spread in such oligometastatic settings, hierarchical 
clustering of Euclidean distances between primary tumors and their metastases was performed in 
these patients. The results are supportive for two patterns of metastatic evolution in LUAD ( Figure 
37): (i) polyclonal spread from the primary tumor and (ii) monoclonal metastasis-to-metastasis 
spread. 
The primary tumor of patient 22 was more closely related to the brain metastasis than to the 
intrapulmonary (of a different lobe in the ipsilateral lung) metastasis. Besides the fact that KRAS, 
ATM, and PTPRD were mutated in all three tumor manifestations, biallelic inactivation of PTPRD, a 
TSG that is frequently inactivated in glioblastoma multiforme and malignant melanoma214, was 
detected only in the primary tumor and the brain metastasis. Conversely, a mutation in VEGFR3 
(gene: FLT4), a TK that is implicated in both the RTK/RAS/RAF and PI(3)K-mTOR pathways,
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Figure 37 | Two patterns of metastatic spread. Hierarchical clustering of SNVs (including silent mutations) and SCNAs of 
sorted tumor populations of four patients with ≥2 metastases. 
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was shared between the primary tumor and the intrapulmonary metastasis. Additionally, of the two 
SCNAs on chromosome 4 that were both present in the primary tumor, a different one was detected 
in the brain and intrapulmonary metastasis, respectively (Appendix I). These data support the idea 
that two clones disseminated from the primary tumor independently and colonized different parts of 
the body (“polyclonal spread”). 
In contrast to patient 22, the metastases of patients 20, 31, and 36 were more closely related to each 
other than to their primary tumors. Known drivers (KRAS: patient 20, 36; EGFR: patient 31) and a 
large number of SNVs and SCNAs in patients 20 and 31, respectively, were ubiquitously present in all 
tumors and can therefore be considered early events in the evolution of these tumors. The tumor 
patient 36, however, was characterized by a substantial number of private events. The phylogenetic 
relationship analysis for all three patients suggests a metastatic cascade, in which one metastasis 
continued to seed other metastases (“metastasis-to-metastasis spread”). This comprised 
contralateral spreads that were either intrapulmonary (patients 31 and 36) or from one kidney to the 
other (patient 20) with durations from 11 months (patient 36) and up to five years (patient 31) after 
the detection of the primary tumors. Notably, besides few additional SCNAs, the metastases and not 
the primary tumor of patient 36 had a mutation in the 3’untranslated region (3’UTR) of the CDKN2A 
gene. Mutations in the 3’UTR of CDKN2A have been previously associated with tumor 
development.215 In addition, patient 31 presented with a decrease of the mutant allele of the EGFR 
L858R mutation during the course of the metastatic disease (VAF: 63%, primary tumor; VAF: 39% and 
33% in the first and second metastasis, respectively). 
 
4.2.8 Multiparameter flow sorting reveals a complex situation with substantial ITH 
In contrast to all other tumors in this cohort, the primary tumor of patient 42 showed more than one 
tumor population in the multiparameter flow cytometry analysis. It consisted of three TTF1-positive 
tumor populations. Of these, one diploid 2.1N population accounted for 33.3% of all cells in the 
tumor, and two aneuploid populations, 3.4N and 4.7N, had shares of 9.5% and 36.4%, respectively, of 
the tumor mass (Figure 38a). A diploid, TTF1-negative population made up the rest (20.8%) of the 
tumor and because no SCNAs or SNVs were detected (Figure 38c, Figure S5), it was considered to 
comprise the normal tumor stroma. Conversely, all three tumor populations were characterized by 
distinct SCNAs (Figure 38c) and a previously reported EGFR exon 20 insertion mutation 
(p.N771delinsGY)216 that is known to confer resistance to EGFR TKIs was ubiquitously present. 
In order to study the relationship among the three tumor populations of this multiploid primary 
tumor, we complemented aCGH analysis with whole-exome sequencing (mean coverage 85x) of all 
sorted populations. Sorting and ultra-deep targeted resequencing (mean coverage 5,864x) with a 
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custom panel of both the primary tumor and the metastasis were performed in replicates to validate 
the detected SNVs and their VAFs. A high correlation of the VAFs was detected for all tumor 
populations (Figure S13 and Figure S14). 
The aCGH analysis demonstrated that all tumor populations were of clonal origin (Figure 38b). This 
was evident from the common aberration pattern on chromosome 5p, which entailed an 
amplification of TERT (Figure 38b, panel 1). We also detected private and shared SCNAs, at least two 
of them of substantial interest for defining the evolution of this tumor. First, the homozygous 
deletion of the gene CDKN2A (9p21), which encodes for the tumor suppressor p16, was exclusive to 
the diploid 2.1N population (Figure 38b, panel 2). Second, a high amplification of the mouse double 
minute 2 homolog (MDM2) oncogene (chr 12) was shared among the 3.4N and 4.7N populations of 
the primary tumor and the metastasis but was absent in the 2.1N population of the primary tumor 
(Figure 38b, panel 3). We confirmed the presence of distinct tumor populations by using p16 IHC on 
large sections of the primary tumor (Figure 39a); only the diploid tumor cells with the homozygous 
deletion of CDKN2A were characterized by the absence of the p16 protein expression. In addition, 
the breakpoint of the CDKN2A aberration (Figure 38b, panel 2) and an SCNA breakpoint on chr7q 
(Figure 38c), both absent in the 3.4N population, indicated a relationship between the 2.1N 
population, the 4.7N population, and the metastasis. 
Mutational analysis validated a total of 96 SNVs and revealed a rather complex picture. Only 27% of 
the mutations were ubiquitous, yet 47% of all SNVs were shared by one or another tumor population 
(Figure 39c). Indeed, the phylogenetic relationship on metapopulation resolution, as analyzed by 
EXPANDS205, indicated a relationship between the 2.1N population and both the 3.4N and 4.7N 
populations (Figure 39b). However, the 4.7N population was most closely related to the metastasis. 
We further investigated regions of LOH to determine if they were responsible for the absence of 
mutations. However, only 5 of 31 SNVs absent in the 3.4N population but shared between other 
tumor populations could be explained by losses of the mutant alleles due to LOH. In contrast, LOH 
was not responsible for the absence of any SNVs in the 2.1N population (Figure 39c). Interestingly, 
two regions affected by LOH indicated a relationship between the 2.1N and the 3.4N population and 
were absent in the 4.7N population and the metastasis. However, a closer analysis of these two 
regions revealed the other homologous chromosome was lost in the 2.1N and the 3.4N population, 
respectively (Figure S15). Conversely, LOH events that were ubiquitous or shared among the 3.4N, 
4.7N and metastatic populations always affected the same chromosome. Notably, the 4.7N 
population and the metastasis lacked most of the LOH events that were found in either the 2.1N or 
the 3.4N population, including LOH of the two aforementioned regions present in the 2.1N and 3.4N 
populations (Figure S15).  
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Figure 38 | Genomic ITH in the multiploid primary tumor of patient 42. The primary tumor of patient 42 consisted of three 
TTF1-positive tumor populations (2.1N: orange, 3.4N: green and 4.7N: blue), whereas only one tumor population (purple) 
was present in the metastasis (a). All tumor populations carried SCNAs (c) that were either ubiquitous (b: chr5p, TERT), 
shared between the aneuploid tumor populations (b: chr12, MDM2), or private to the 2.1N population (b: homozygous 
CDKN2A deletion, chr9p). 
 
 
Figure 39 | Clonal tumor evolution in patient 42. IHC for p16 (a) validated the loss of p16 expression in the 2.1N population 
of the primary tumor with the private homozygous deletion of CDKN2A. The phylogenetic relationship on metapopulation 
resolution based on SCNAs as calculated by EXPANDS (b). Overview of 96 high confidence SNVs with their VAFs (c). Image b 
was produced by Dr. Noemi Andor (Stanford). 
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5. Discussion 
Many computational methods have been developed to discover copy number aberrations directly 
from DNA microarrays 217–220 or sequencing data221,222, including aCGH. Discovering copy numbers 
and VAFs in an absolute scale is biologically more relevant223, yet more challenging. This is because 
the detection of absolute values in a tumor can be affected by two confounding factors: (i) tumor 
purity, i.e. the fraction of tumor cells within a heterogeneous cancer sample, and (ii) tumor ploidy, 
the baseline copy number of genomic segments or entire chromosomes223,224, both of which are 
unknown and themselves need to be estimated. One promising approach to exclude such prior 
estimations of ploidy and purity is flow cytometry. It can increase purity by sorting only the cells of 
interest, while quantifying the ploidy of a tumor at the same. 
Previous studies have applied such a sorting approach on nuclei extracted from tumor tissues in 
order to genomically characterize them.225–227 These studies have sorted nuclei solely based on their 
DNA content. However, around 50% of human tumors are diploid (Figure 40) and can therefore not 
be distinguished from normal, diploid cells based on their ploidy alone. Currently, there is no method 
that allows for the flow cytometric enrichment of tumor nuclei from diploid tumors. To overcome 
these limitations, we aimed to improve the nuclei flow-sorting method from a simple ploidy-sorting 
approach to a tumor marker-assisted multiparameter flow-sorting technology. This allows for the 
genomic characterization, including the detection of SCNAs and SNVs, of diploid tumors to an 
unprecedented purity. 
 
Figure 40 | Distribution of ploidy and purity across 10 cancer types (data retrieved from 
https://www.synapse.org/#!Synapse:syn1710466.2, version 2 (547.909 KB, modified on 2013-03-20), ref
126
); tumor purity 
(top) and ploidy (pirate plot, bottom). LUAD, lung adenocarcinoma; LUSC, lung squamous cell; HNSC, head and neck 
squamous cell; KIRC, kidney renal cell; BRCA, breast; BLCA, bladder; CRC, colorectal; UCEC, uterine cervix; GBM, 
glioblastoma multiforme; OV, ovary. Box plots show the median, first quartile and third quartile of purity for each cancer 
type. Diploid samples are designated in blue, aneuploidy tumors in pink, and hypodiploid tumors in orange. Note: Ploidy 
axis is limited to a ploidy of five for visualization purposes. Tumors with a ploidy>5 are plotted under 5+. 
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Part A 
Part A of this thesis demonstrated the feasibility of this approach as a proof-of-concept for two 
markers: TTF1 and SOX10. They were chosen (i) because they are lineage markers for LUAD and 
malignant melanoma, respectively, (ii) because they are expressed by a large number of tumors 
(LUAD: 72% TTF1-positive; melanoma: 100% SOX10-positive), and (iii) because these two proteins are 
transcription factors and therefore localized in the nucleus. The latter point is important because the 
cellular integrity of cells is disrupted when frozen tissues are thawed or when FFPE tissues are 
digested. Consequently, only nuclei and not cells can be obtained from such archived materials. 
The cell culture experiments provide evidence that both the anti-TTF1 antibody and the anti-SOX10 
antibody can be used to detect TTF1 and SOX10, respectively, in nuclei extracted with our protocols 
and under our experimental conditions. While isotype controls are often used to quantify unspecific 
background staining in flow cytometry, we think that the best control to measure specificity of 
immunostainings is to mix positive and negative controls before the addition of the antibody. By 
doing so, we showed that both antibodies are sensitive and specific in separating TTF1- or SOX10-
positive from TTF1- or SOX10-negative nuclei. 
When we started to apply this method to human tumors, we initially focused on samples that were 
purely diploid – as indicated by the absence of a prominent aneuploid peak – and positive for the 
markers TTF1 or SOX10. We identified four samples that matched these criteria: two diploid, TTF1-
positive LUADs and two diploid, SOX10-positive malignant melanomas. As expected, the diploid 
peaks split into a positive and a negative population according to the antibody used. We sorted each 
of these populations and performed copy number analysis by aCGH. Distinct SCNAs in the diploid, 
marker-positive fraction revealed their tumor origin, whereas no SCNAs could be detected in the 
diploid, marker-negative populations. We hypothesized that diploid populations without any SCNAs 
were of non-tumor origin. This was supported by the observation that we did not detect any SNVs in 
409 cancer genes in these populations as compared to non-tumor control DNA for three patients. In 
addition, the VAF distribution pattern was identical to those of the tumor-free controls. Many tumors 
are highly intermixed with stromal and immune cells, and it is likely that they accounted for the 
diploid, marker-negative populations in our experiments. Based on these results, we propose the use 
of DNA from these populations as a surrogate for germline DNA in situations where normal germline 
DNA of the patients is not available. This is often the case in retrospective studies, where most of the 
patients have already died from their disease at the time of investigation. Matched normal DNA is 
important to increase sensitivity and specificity of SNV detection in tumors, as demonstrated by a 
recent study that has showed that 31% (targeted) or 65% (exome) of mutations have been falsely 
considered true positive SNVs when matched normal DNA has not been used for the analysis.228 
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The nuclei sorting technique was initially refined with the intention of sorting diploid tumor nuclei 
from bulk tissues of diploid tumors only. However, during screening and flow cytometric analysis of 
multiple tumors, we found diploid, marker-positive populations in four otherwise aneuploid tumors: 
three malignant melanomas and one LUAD. In contrast to the LUAD, where the diploid TTF1-positive 
population was of non-tumor origin, all three diploid, SOX10-positive populations in the melanomas 
were of tumor origin, because they had distinct SCNAs. These diploid tumor populations were 
clonally related to their aneuploid counterparts as indicated by a large number shared SCNAs. This – 
along with the fact that the ploidy of the aneuploid populations was approximately twice the ploidy 
of the diploid tumor populations – suggests that the aneuploid tumor populations have emerged 
from a cell of the diploid tumor population or from a common diploid precursor cell by a WGD event.  
It has been recently demonstrated that 40% of tumors across 10 different solid cancer types are the 
consequence of WGDs.126 To the best of my knowledge, the co-existence of diploid and aneuploid 
tumor populations in single tumor lesions has not been reported yet in malignant melanomas. In 
fact, this situation is limited overall to two case reports of prostate carcinoma.225,229 Another study in 
head and neck squamous cell carcinomas has reported the presence of diploid tumor populations 
together with aneuploid populations230, but lacks further genomic validation that the diploid 
population is of tumor origin, such as the presence of SCNAs or SNVs in these cells. That study has 
used cytokeratin as a marker of epithelial origin and has concluded that cytokeratin-positive, diploid 
cells are tumor cells. However, as we have learned from a similar case of a TTF1-positive LUAD in Part 
A of this thesis, diploid TTF1-positive populations are no necessarily tumor because TTF1 can be 
expressed by normal alveolar cells similarly to cytokeratin, which is also expressed by normal cells of 
epithelial origin. Validation is therefore necessary in suspected diploid tumor populations, either by 
IHC or by detection of multiple SCNAs or SNVs. 
The fact that we have detected three cases with such diploid/aneuploid coexistence, suggests that 
this is not an uncommon state in tumors, or at least in melanomas. This is not surprising, given that 
all aneuploid tumors eventually originate from a normal diploid cell that became malignant during 
the initiation of tumorigenesis. Two possibilities could explain this co-existence. First, we could just 
have sampled at the right moment, meaning that the tumor biopsy was taken shortly after this WGD 
event, where the time interval was too short for one of the populations to sweep over the entire 
tumor and to eradicate the other tumor population. This implies however, that one population is 
better adapted than the other and that this adaption goes hand in hand with a survival and growth 
benefit. A second explanation, however, is that both populations are present because they cooperate 
and depend on each other. This theory of “cooperation among tumor cells” is not new in cancer 
research, and it is thought to be linked to at least three cancer hallmarks: (i) angiogenesis, which 
results in additional blood supply, the products of which, oxygen and nutrients, help all of the nearby 
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cells and not just the cell that secreted the vascular endothelial growth factor (VEGF); (ii) self-
sufficiency of growth signals, where cancer cells produce several growth factors that act in a 
paracrine fashion on other cancer cells or stromal cells and activate them to release other growth 
factors; and (iii) tissue invasion and metastasis, in which proteases expressed from cancer-associated 
stromal cells and cancer cells themselves contribute to neoplastic progression by degradation of the 
extracellular matrix, allowing further proliferation, tissue invasion, and eventually metastasis of other 
cells.231 Indeed, the hypothesis of tumor cell cooperation may explain some of the observations 
about solid cancers, such as the non-uniform abundance of certain proteins, including growth factors 
in IHC.232,233 However, a more comprehensive transcriptomic and proteomic analysis would be 
needed to clarify the situation in our samples. Nevertheless, this co-existence emphasizes that 
diploid tumor cells can persist after the development of an aneuploid clone and suggests that they 
do so for a deeper biological reason, which probably contributes to further local tumor progression. 
In one of the three above-discussed patients with melanoma, tissue of two additional metastatic 
lesions was available. In contrast to the local relapse, both the lymph node and the skin metastases 
were entirely aneuploid. We took a deeper look at the tumor evolution in this patient, by performing 
aCGH and targeted sequencing of frequently mutated melanoma genes from the local relapse and 
both metastatic sites. Overall, the majority of SCNAs and SNVs were ubiquitously present in all tumor 
populations, yet some private events suggest that the lymph node metastasis derived from the 
diploid rather than from the aneuploid tumor population of the local relapse. Conversely, the skin 
metastasis was a direct outgrowth of the aneuploid tumor population of the relapse, indicated by the 
observation that they shared all SNVs and SCNAs. The data of this patient are consistent with an early 
acquisition of mutations. These were probably induced by ultraviolet (UV)-light exposure, because, 
despite the fact that we detected only 16 with our targeted panel, 15 were C>T:G>A transition 
mutations, which is a signature of melanomas from sun-exposed skin.234 Our data indicate that a 
malignant, diploid precursor had all these SNVs and had experienced losses of chr9, chr12 and chr17, 
which resulted in mutations of PTPRD (chr9), ARID2 (chr12), and TP53 (chr17) with VAFs of 100% due 
to the loss of their wild-type alleles. Different chromosomes or chromosome parts were then further 
lost prior to or during a WGD. The aneuploid tumor population of the relapse could therefore be the 
result of a WGD of its diploid counterpart, whereas the lymph node metastasis probably emerged 
from a different WGD of another precursor cell (Figure 24b). However, it cannot be determined 
whether this WGD event happened before metastatic dissemination, during the migration or after 
colonization at the lymph node itself. The fact that each population acquired additional private 
aberrations supports a model of parallel evolution. These private alterations also included a focal 
aberration pattern on chr4 in the lymph node metastasis (Figure 23e) that was similar to another 
patient with multiple focal deletions that were scattered across chr9p (Figure 22e). In both cases, 
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these focal SCNAs culminated in aberration patterns consistent with chromothripsis235, a 
phenomenon that has been reported in melanoma just recently.236 
In summary, we have provided a tool that allows the enrichment of nuclei from bulk tumor tissues 
based on their expression of specific proteins. The fact that we detected mutations with VAFs of 
100% in all sequenced samples proves, without the necessity of estimation or computational 
deconvolution, (i) that all cells within the cancer harbor this mutation, (ii) that all alleles are affected, 
and (iii) how pure the DNA is that is obtained from sorting tumor populations using this approach. It 
therefore provides a possibility to quantify absolute copy numbers and absolute VAFs in diploid 
tumors and allows studying tumor evolution in tumors with coexisting diploid/aneuploid populations, 
a phenomenon that would be missed by bulk analysis. These data suggest that the majority of SCNAs 
in melanomas are early events or happen at least before WGD because they are shared in large 
numbers between diploid and aneuploid populations. This is known for SNVs in malignant 
melanomas because UV-exposure is the main driver of this disease and leads to a steady 
accumulation of many mutations237, yet that the majority of SCNAs are present before 
aneuploidization has not been reported previously. 
This approach is therefore applicable for the study of diploid tumors in malignant melanoma and 
LUAD, but can be extended to other cancers. Another good candidate is prostate cancer, because 
65% of all prostate cancers are diploid223 and 40-60% harbour the TMPRSS2–ERG gene fusion that 
results from a chromosomal rearrangement.238,239 This gene fusion leads to an androgen-dependent 
transcription and nuclear expression of the transcription factor ERG of affected prostate cancer 
cells.240 This could be exploited for ERG-assisted ploidy flow sorting of prostate cancer nuclei. 
Furthermore, as long as cells or nuclei of interest express a specific protein, multiparameter flow 
cytometry is able to sort these and provide them for subsequent analyses.  
 
Part B 
In Part B of this thesis we applied the multiparameter flow-sorting approach on a cohort of matched 
primary/metastatic LUADs. We chose this approach because LUADs have the lowest tumor purity 
(mean: 46%) among solid cancers223,126, which is probably one of the reasons why data of primary 
tumors with matched metastases are lacking in this tumor entity. Previous studies on ITH in LUAD 
have focused mainly on the two main oncogenic drivers KRAS and EGFR241 (reviewed in 242) or have 
been performed in single biopsies or unmatched tumors of individual patients.6,243 Hence, despite the 
fact that these studies have provided a landscape of genomic alterations in LUAD, it is currently 
unknown to what extent chromosomal aberrations and mutations in other cancer genes are 
propagated from the primary tumors to metastases. Furthermore, the role of clonal selection during 
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this process remains largely unidentified. To address these unresolved questions, we applied a 
comprehensive genomic analysis of highly purified clonal tumor cell populations from matched 
primary-metastatic biopsies that allows for inferring the clonal relationship of 16 LUADs across time 
and space. We demonstrated that this approach works for both fresh-frozen and FFPE tissues and 
most importantly for samples with a low tumor purity and diploid tumors that cannot be 
distinguished from diploid normal cells by DNA content analysis alone. To the best of my knowledge, 
this study represents the largest effort so far to elucidate the extent of inter-lesion heterogeneity of 
SCNAs and cancer gene mutations in longitudinal biopsies of matched primary and metastatic LUAD.  
The prevalence of mutations of known cancer genes that we found is in line with previous 
studies.53,58,56 In addition, the high purity of sorted tumor cell nuclei enabled us to study VAFs and 
absolute copy numbers at a previously unmet resolution. As expected, biallelic inactivation mainly 
affected TSGs, but surprisingly, the oncogenes KRAS and EGFR were also mutated with a VAF of 100% 
in three patients. Most importantly, the VAFs of mutations did not change significantly over the 
course of metastatic disease. Indeed, the correlation of VAFs with their absolute copy numbers 
indicates that the majority of ubiquitous SNVs were truncal and therefore early events in 
tumorigenesis. Conversely, the observation that the VAFs of shared and especially of private 
mutations were significantly lower, suggests that they were present only in a sub-fraction of cancer 
cells within the tumor and therefore occurred at later stages of tumorigenesis. The fact that these 
private SNVs in the primary tumor were – by definition – not propagated to the metastasis calls into 
question their impact in conferring metastatic risk. However, we might not have detected all 
metastatic sites in each patient, and they could impact local tumor progression. In addition, they 
might be selected under specific circumstances such as targeted therapy, which has been reported, 
for instance, for subclonal EGFR T790M mutations.244 Nevertheless, their pure presence does not 
necessarily implicate any evolutionary selection, as subclonal mutations with low VAF were shown to 
often result from neutral evolution.245 
CIN and aneuploidy are regarded as hallmarks of cancer246, and inferences about the timing of 
metastatic dissemination have to take into consideration the possibility of an inherent CIN of tumors. 
The fact that SCNAs were detected in all tumor populations indicates a history of CIN throughout the 
tumors of our cohort. Chromosomally unstable tumors are expected to continuously accumulate 
large-scale genomic alterations over time, resulting in a higher burden of SCNAs at metastatic sites 
than in primary tumors. Indeed, studies in other solid cancers, e.g. pancreatic cancer247, renal cell 
carcinoma248, or prostate cancer249 have found that the number of SCNAs is higher in metastases 
than in primary tumors, which argues for a continuous impact of CIN on the tumor cells. In contrast 
to these studies, we detected no increase in the number of SCNAs in metastases compared to 
primary tumors. In fact, 88% of SCNAs were propagated from the primary tumors to the metastases 
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and 87% of all SCNAs detected in the metastases were shared with the primary tumor. This is 
surprising given that the median time interval from primary tumor detection to the occurrence of the 
first biopsied metastasis was almost one year. Such little ITH between the primary and metastatic 
sites indicates that most SCNAs and SNVs were early events and manifested in the primary tumors 
before metastatic dissemination.  
This high primary-metastatic concordance might be expected for SNVs in a cancer that accumulates 
mutations early mainly due to the exposure of carcinogens in tobacco smoke56, yet this has not been 
previously reported for SCNAs in LUADs and is in agreement with published data of high 
primary/metastatic SCNAs concordance in other cancers.250,251 In fact, a study in lung cancer patients 
has investigated SCNA-patterns at single cell resolution in CTCs – the tumor cells that circulate in the 
blood of cancer patients and are thought to be the founders of metastases. This study has detected 
that CTCs exhibited copy number patterns that are reproducible between individual CTCs from the 
same patient.252 Similarly, a recent study of single cells in breast cancer has found that most SCNAs 
happen in a short period of crisis followed by stasis and expansion of stable clones without much 
further change, resulting in rather homogeneous copy number patterns.127 Such a saltation theory of 
punctuated evolution implies the presence of one dominant large clone, the so-called “hopeful 
monster”, and is compatible with ongoing selection and gradual, yet slow, changes. According to this 
theory, additional changes are low, compared to the events that happened in short punctuated 
bursts at the early stages of tumor evolution and lead to a rather chromosomally stable expansion of 
a clone that eventually forms the tumor mass. Such a theory could explain the observation in our 
cohort that not only most of the SCNAs were shared between primary tumors and their metastasis, 
but also that changes in absolute copy numbers were rarely detected.  
The idea that most SCNAs are shared between the primary tumor and the metastasis because they 
occur in the early steps of tumorigenesis, also assumes that they are truncal and that the primary 
tumor consists of a rather homogeneous population of cells in respect to SCNAs. Indeed, metastases 
are seeded by single or a few cells from the primary tumor; hence if the primary tumor was 
heterogeneous, a reduction in genetic diversity would be seen at metastatic sites, and we would 
have detected a decrease in the number of SCNAs that are propagated from the primary tumor to 
the metastases. In addition, cells have to undergo many additional cell divisions at metastatic sites in 
order to form a clinically detectable tumor mass. If these metastatic founders are chromosomally 
unstable, a higher discrepancy of SCNAs and their absolute copy numbers between two lesions 
would be expected as compared to what we have identified in our cohort. Therefore, it is possible 
that LUADs in this cohort received the majority of their SCNAs through a punctuated evolution 
followed by a rather stable local and metastatic tumor progression (Figure 41b,c). We note that 
gradual changes could behave similar, but only under the assumption of very long time periods for 
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these changes to happen (Figure 41a). Otherwise, it would not be plausible that chromosomally 
unstable tumor cells stop to “destroy” their genomes. CIN eventually result in aneuploidy, but not all 
aneuploid cells have to be chromosomally unstable. This phenomenon of aneuploid tumors with a 
uniform, stable karyotype has been reported, but has received much less attention than CIN.246,253 
 
 
Figure 41 | Models of evolution in the LUAD cohort. Investigating SCNAs at a single time point provides only a snapshot in 
the evolution of a tumor. With our analysis we cannot distinguish, if the SCNAs in the primary tumor are the consequence 
of a gradual accumulation of alterations in a chromosomally unstable tumor over time (a), or the consequence of a single, 
punctuated event that is not repeated (b). However, we analyzed clonally related metastases and found that they share 
most of their SCNAs with the primary tumors. This can be explained by two models: (i) if the primary tumor is the result of 
an early punctuated burst of evolution in the early stages of tumor progression (b), is might not exhibit high levels of CIN. 
Therefore, the primary tumor could be a “hopeful monster” that undergoes stable clonal expansions during metastatic 
development (c, upper panel); (ii) if the primary tumor has evolved gradually, it is probably chromosomally unstable, and 
CIN is unlikely to be turned off by the tumor itself. Under this assumption, the little increase of SCNAs at metastatic sites 
that we have detected might result from a negative selection of new SCNAs that emerge over the course of metastatic 
progression (c, lower panel). 
 
However, caution should be exercised from which viewpoint the knowledge about CIN is generated. 
In this LUAD cohort, SCNAs were investigated at the population level – consisting of many thousand 
cells with the same ploidy – and not at single cell resolution. This is a difference, because what is 
seen as the result of a population does not have to be true for individual cells. It has been 
emphasized that stable karyotypes at the population level can persist, despite high rates of ongoing 
a                         b 
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CIN in single cells.159 In such steady-state conditions, new SCNAs are established in the population 
only after long time periods, at least as long as the environment remains constant. In fact, it has been 
documented that the karyotypes of some cell lines have remained relatively unchanged despite the 
fact that they have been cultured over years separately in different laboratories.254,255 This argues for 
a selection against the emergence of new SCNAs under steady-state conditions. However, if external 
selection factors such as specific therapies are applied, CIN of individual cells can manifest itself as 
karyotypic heterogeneity. The cell line MCF-7, for instance, has been found to be karyotypically 
stable over generations until a selection for a cytotoxic resistance has been applied.256 Therefore the 
low ITH that we detected in our cohort of primary-metastatic LUADs on the population level could 
also be the result of a negative selection of new emerging, deleterious copy number alterations 
(Figure 41c). To test these hypotheses one would ultimately need to investigate single cells and check 
for the presence or absence of intermediate genotypes. However, despite advances in single cell 
technologies, this is a labor- and cost-intensive endeavor that would have gone beyond the scope of 
this thesis. 
CIN and aneuploidy have been previously linked to a dysregulation of the ataxia-telangiectasia 
mutated (ATM)-p53 pathway.257 p53 is a tumor suppressor and regarded as “the guardian of the 
genome”258 because of its central role in organizing whether a cell responses to various types of 
stress such as DNA damage with apoptosis, cell cycle arrest, senescence, DNA repair, cell metabolism 
or autophagy.259 During normal homeostasis, p53 levels are stabilized by two mechanisms: (i) 
continuous degradation of p53 in proteasomes mediated by ubiquitination through the E3 ubiquitin 
ligase Mdm2; and (ii) phosphorylation by ATM, ATR and other kinases stabilizes the p53 protein and 
promote its DNA binding and subsequent transcription of p53 target genes.260 Recent studies have 
shown that p53 is not only activated by DNA damage but also by aneuploidy.158,257 The activation of 
p53 in aneuploid cells is mediated through ATM in the presence of elevated levels of reactive oxygen 
species, which are increased probably due to a higher energy consumption of aneuploid cells.261,262 
Therefore, dysregulation of the ATM-p53 pathway, for instance due to mutations in the TSGs TP53 
and ATM, or amplifications of the oncogene MDM2, has been implicated with tumorigenesis. In our 
cohort, biallelic inactivation of TP53 or ATM correlated with a significant high burden of SCNAs. This 
is in line with previous data that have found the number of SCNAs to be higher in tumors with TP53 
mutations.126,263,264 In addition, few private SCNAs were evident at metastatic sites in TP53-mutated 
tumor in our cohort, which suggests a late dissemination of the metastatic clone from the primary 
tumor. In fact, we observed that the time interval between primary and metastatic tumor detection 
was the shortest in tumors with biallelic inactivation of TP53 or ATM. This is in agreement with 
previous reports that have shown that loss of p53 accelerates growth in aneuploid tumors257,265, 
suggesting that a fast proliferation of TP53- or ATM-mutated tumors did not allow enough time to 
Dissertation Thomas Lorber 
80 
accumulate many additional SCNAs. Of note, all diploid tumor populations were TP53 and ATM wild-
type and also had the overall lowest amounts of SCNAs among this cohort, which is in line with 
previous studies that have found (i) that diploid tumors have fewer genomic aberrations than 
aneuploid tumors266, and (ii) that TP53 mutations occur more often in aneuploid than diploid 
tumors.126,267 Interestingly, only the aneuploid tumor populations in the multiploid primary tumor of 
patient 42, and not the diploid tumor population had a high-level amplification of the MDM2 
oncogene, potentially correlating with a loss of p53 function due to overexpression of Mdm2. 
Inactivation of p53 has been previously associated with tolerance of tetraploidy, the result of a 
WGD.265,268–270 The correlation of TP53 mutations and aneuploidy in our cohort therefore indicates 
that this association also applies to LUADs. 
The early emergence of metastases in tumors with an inactivated ATM-p53 pathway suggested that 
these tumors follow the linear progression model of tumor evolution. However, our analysis of 
genetic divergence also discovered some primary-metastatic pairs with clear signs of parallel 
evolution, which is associated with an early dissemination of the metastatic founder clone from the 
primary tumor. This is in line with previous data that have found evidence for branched evolution in 
breast cancer271, renal cell carcinoma272 and among other cancer types in a recent pan-cancer 
analysis.273 Despite these observations, we were not able to detect a correlation between the type of 
metastatic progression (linear or parallel) and the relative time interval between primary and 
metastatic tumor detection. For instance, the P/M divergence was similar in patient 12 and patient 
49, yet the time between primary and metastatic tumor detection was 2 months and 12.7 years, 
respectively. One has to be careful, however, because the tumor of patient 49 was diploid and 
characterized by only a few SCNAs. In such cases, an absolute small number of additional alterations 
has a relatively strong effect on the value of the P/M divergence. Nevertheless, genetic distance 
between two lesions is unlikely to correlate only with the time difference in clinical detection. 
Pancreatic adenocarcinoma, for instance, was believed to metastasize early because many patients 
have metastases already at diagnosis. However, this was an oversimplified assumption, as 
demonstrated by whole-genome sequencing data, which have revealed that late diagnosis, and not 
early metastasis, is responsible for this observation. In fact, it has been suggested that the metastatic 
process took decades.274 This is because other parameters, such as the timing of divergence between 
the primary tumor and the metastases, the exposure to mutagenic substances, intrinsic genomic 
instability, and the dynamics of evolution in each lesion unequivocally impact the shaping of cancer 
genomes. 
To study whether metastases are the result of repeated seeding from the primary tumor or arise 
from a previously established metastasis, multiple tumors of individual patients have to be 
investigated. Our cohort included four patients with oligometastatic disease. Hierarchical clustering 
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of SCNAs and SNVs of all tumor lesions indicated that both primary tumors and metastases can 
spread to further metastatic sites. Patient 22, for instance, showed two separate waves of metastatic 
spread: from the primary tumor (i) to a brain and (ii) to an ipsilateral lung metastasis. In contrast, in 
three other patients (patients 20, 31, and 36) the primary tumor was an outgroup to all metastases, 
i.e. all metastases were more closely related to a common ancestor than to their most recent 
common ancestor with the primary tumor. Likewise, a recent report has demonstrated that the 
primary tumor has been an outgroup to all metastases in two LUADs.273 This relatively high 
proportion of patients with tumors that evolve through a metastatic cascade might have important 
clinical implications. It provides a strong argument in favor of aggressive local treatment of all 
metastatic sites in patients with synchronous or metachronous oligometastatic LUADs.275,276  
Cancer evolution is a complex process and, despite intensive research, insufficiently understood. In 
this study an extraordinary example of ITH and cancer evolution was observed in a multiploid 
primary tumor and its metastasis (patient 42). While the metastasis most likely emerged from the 
4.7N population of the primary tumor, analysis of SCNAs and SNVs in the highly purified tumor cell 
populations of the primary tumor did not reveal a clear picture of either a linear or parallel evolution. 
Interestingly, the genomic data were more consistent with the 4.7N population being a hybrid of the 
2.1N and 3.4N populations. The idea that tumor hybridization contributes to cancer progression was 
introduced more than 100 years ago.277–279 Cell fusions – which occur naturally during fertilization, 
the formation of placenta and muscle fibers, and bone homeostasis280 – have been described as 
occurring between cancer cells and other cell types both in in-vitro and in in-vivo mouse models.281–
283 In humans, however, they are difficult to detect because of the lack of an appropriate genetic 
marker. Hence, the most convincing result in human cancer derives from a single case report of a 
woman that developed renal-cell carcinoma after an allogenic bone marrow transplantation from a 
male donor. Donor Y chromosomes were found in the tumor cells, suggesting that a cell fusion 
between a donor and a recipient cell had taken place.284 Despite these limited data regarding human 
cancers, the concept of cell fusion has been recently revitalized as one of the forces that drive cancer 
progression.280 To provide evidence for a tumor-tumor cell fusion in patient 42 of our cohort, the 
mutational landscape that we found in each sorted tumor cell population would need to be 
demonstrated at single cell resolution. However, as mentioned earlier, this would go beyond the 
scope of this work. Even though a definitive answer for the evolution of the multiploid tumor in 
patient 42 remains outstanding, we provide evidence that cells of the same ploidy share private 
genomic alterations that would be missed by an analysis of bulk material and demonstrate that 
cancer evolution is more complex than currently thought. 
Nevertheless, this study has certain limitations. Array-CGH, for instance, cannot detect chromosomal 
gains and losses without copy number changes. Therefore, balanced chromosomal alterations, such 
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as translocations, inversions, or mosaicism are not identified. Further, the chip size used for our 
experiments allows the detection of aberrations with a minimum size of 35.2 Kb. Hence, smaller 
aberrations are not discovered. However, our aCGH data are at high resolution as compared to 
conventional comparative genomic hybridization (CGH), for which the maximal resolution is around 
10 Mb.285 In addition, aCGH provides copy numbers and aberrations across the entire genome, 
including non-coding regions, whereas studies that detect copy numbers from whole-exome 
sequencing are limited to coding regions only. We acknowledge that our focus on the targeted 
sequencing of cancer genes does not allow for the detection of mutations that occur in other genes 
previously not associated with cancer. However, our focus is on ITH of important cancer driver gene 
mutations rather than the discovery of new mutations in other genes. Regardless, it is very likely that 
many mutations detected in smoking-related LUADs are passenger rather than driver mutations. We 
are aware that the medium size of our cohort might be too small to find further significant 
correlations. Yet, sample size is less relevant in qualitative research than in quantitative approaches, 
and we are convinced we have provided qualitative research by genome-wide detection of SCNAs 
and ultra-deep sequencing of well-known cancer genes in tumor populations that were sorted to a 
previously unprecedented purity in LUADs. 
The aim of this study was to provide a comparison of matched primary-metastatic LUAD pairs with 
material collected over two decades at the IfP. In summary, a high concordance of SCNAs and SNVs 
between primary tumors and metastases was detected that is responsible for the observation of 
stable ploidies over long periods of time. This overall low ITH between primary and metastatic sites 
suggests that most SCNAs are early events that accumulate in the primary tumors before metastatic 
dissemination and that CIN is low on the population level. Similarly, low ITH of 21 cancer gene 
mutations has been recently revealed in primary LUADs using a multiregion sequencing approach6. 
This observation is hereby extended to include mutations in a large number of other cancer-relevant 
genes and, to the best of my knowledge, for the first time on the level of copy number aberrations in 
LUADs.  
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6. General Conclusion 
In this work, we have presented a technology that increases the purity of tumor DNA by sorting 
nuclei according to their DNA content from bulk tissues. Most importantly, we have demonstrated 
that the addition of tumor lineage markers allow for the enrichment of tumor nuclei from diploid 
tumors and tumors of low purity. Multiparameter nuclei flow sorting allowed us to study 
chromosomal aberrations and their copy numbers as well as mutations and their VAFs to a previously 
unmet level of precision. This has been demonstrated on three levels: (i) the detection of SNVs with 
VAFs of 100%; (ii) the identification of multiple tumor populations with distinct private mutations in 
individual, single tumor lesions; and (iii) the fact that the DNA of the sorted non-tumor populations 
can serve as a germline control in order to identify the somatic nature of genetic alterations. 
We applied this refined nuclei flow-sorting technology to a cohort of 16 patients with primary LUAD 
and their matched metastases. We validated their clonal relationship by the presence of common 
SCNAs and mutations and found that the majority of alterations were shared between primary 
tumors and their metastasis. In fact, all but one tumor consisted of only tumor cells with a single 
ploidy and the combined analysis of SCNAs and VAFs of SNVs indicated that ubiquitous mutations 
and aberrations are truncal. This resulted in the initial observation by flow cytometry that tumor 
ploidy remained unchanged over the course of metastatic disease. This suggests that either the 
genomes of LUADs are remarkably stable after the primary tumor has been established – despite a 
history of CIN evident from the presence of SCNAs – or that the majority of new aberrations are 
deleterious and therefore negatively selected in tumors with ongoing CIN. Nevertheless, the high 
concordance of alterations between primary tumor and metastatic sites provided evidence that the 
majority of SCNAs and SNVs were present at the primary site before metastatic dissemination, which 
suggests that they can already be detected in the primary tumors.  
Genomic characterization of high-purity samples at an appropriate depth might therefore be 
sufficient to identify the majority of SCNAs and SNVs in relevant cancer genes that are propagated 
from primary tumors to their metastases. Additionally, the observation that metastases are the 
source of further metastatic spread in three out of four patients has clinical implications; in such a 
situation, the removal of the primary tumor alone would fail to halt further metastatic progression. 
In the era of personalized medicine, further approaches in large cohorts are needed to understand 
how CIN and ITH impact the biology of LUADs that have been treated with targeted therapy. One 
such approach is the TRACERx (TRAcking Cancer Evolution through therapy [Rx]) lung research 
project by Cancer Research UK. This project aims to uncover the mechanisms of lung cancer 
evolution by analyzing ITH using multiregion sequencing of matched primary and metastatic sites to 
define the relationship between ITH and the clinical outcome of more than 800 NSCLC patients. 
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Supplementary Figures 
 
Figure S1 | Characteristics of the seventh edition of the TNM staging system for lung cancer (adapted from ref
286
 and 
modified). 
SUPPLEMENTARY FIGURES 
99 
 
Figure S2 | Filter guide of the sorting device. A BD-Influx™ Cell Sorter (University Hospital Basel Nr.2) was used for all flow-
sorting experiments. DAPI (DNA content) intensity was quantified with the FL9 460/50 and TTF1 or SOX10 intensity via the 
secondary Alexa647-coubled antibody with FL6 670/30.  
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Figure S3 | Thyroid gland metastasis of a TTF1-negative LUAD. (a) IHC for TTF1. TTF1 is expressed by normal thyroid 
follicular cells. (b) Multiparameter flow sorting detected these cells as a diploid, TTF1-positive (2N TTF1+) population. 
Consequently, no SCNAs were present in this population (c). In contrast, the aneuploid population (AN) carried many 
SCNAs. Note: These are data from patient 12 from the LUAD cohort from Part B of this thesis. 
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Figure S4 | Comparison of mutations in DNA of sorted diploid, SCNA-negative populations versus tumor-free control 
DNA, and DNA of sorted tumor populations. Somatic and selected germline variants are included to strengthen the fact 
that both germline and somatic mutations with VAF > 80% can be detected in sorted tumor populations. Note: These are 
data from patient 48 from the LUAD cohort from Part B of this thesis that was sorted with DAPI for ploidy only. 
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Figure S5 | Comparison of mutations in DNA of sorted diploid, SCNA-negative populations versus tumor-free control DNA 
and DNA of sorted tumor populations. Note: These are data from patient 42 with a multiploid primary tumor from the 
LUAD cohort from Part B of this thesis. 
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Figure S6 | Clonally unrelated LUAD cases. Three patients were excluded from the cohort of Part B (clonally related 
LUADs). In all three patients, not a single breakpoint (b,d,f) or SNV (a,c,e) was shared between the two tumors in each 
patient. Note that whole chromosomes or whole chromosome arms might be gained or lost in both lesions. However, they 
were not considered evidence for a clonal relationship. A clonal relationship requires the presence of SNVs and 
intra-chromosomal breaks, and both were absent in these three patients. 
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Figure S7 | Localization of primary tumors and their metastases for the 16 patients of the clonally related cohort. The 
colors indicate the four patients with multiple metastases: patient 20, light blue; patient 22, pink; patient 31, green; patient 
36 orange. Note that in these four patients the arrows do not indicate a directionality or relationship of any kind. The 
numbers correlate with the size of the circles and indicate the number of patients (n = 16) with primary tumors at a specific 
lobe. 
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Figure S8| Hierarchical clustering of Euclidean distances based on SCNAs of all sorted tumor populations. Tumors of 
individual patients (P#) are clustered closer to each other than to tumors of other patients. One exception is the diploid 
tumor of patient 42 (P42:N0207A), which is clustered with diploid tumors of other patients. Interestingly, this clustering 
was able to identify three groups, which are represented by their respective ploidies. 
 
 
 
Figure S9| Violin Plots for VAFs. The VAFs of SNVs were plotted according to their presence in all (ubiquitous), more than 
one but not all (shared, applicable for the four patients with nMET >1), or just one (private) tumor biopsy. The differences are 
significant (Mann-Whitney-Wilcoxon Test; ***: p-value < 0.001) 
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Figure S10 | Scatter plots for VAFs of ubiquitous SNVs per patient. VAFs of mutations shared between the primary tumor 
(x-axis) and the first biopsied metastasis (y-axis). Patient 42 is excluded, due to the presence of multiple populations in the 
primary tumor. The correlation among the cohort (top left plot) is linear and significant (p < 0.001). P, patient; M1, first 
biopsied metastasis 
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Figure S11 | Scatter plots for copy numbers of ubiquitous SNVs per patient. The copy numbers of mutations shared 
between the primary tumor (x-axis) and the first biopsied metastasis (y-axis). Patient 42 is excluded, due to the presence of 
multiple populations in the primary tumor. The correlation among the cohort (top left plot) is linear and significant 
(p<0.001). P, patient; M1, first biopsied metastasis 
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Figure S12 | Variant allele frequencies and copy numbers of all mutations detected in this cohort. Density plot of the 
absolute copy number (x-axis) and VAF (y-axis) of the mutations. Note that the majority of non-ubiquitous (shared or 
private) SNVs accumulate at lower VAFs, indicating a non-truncal and therefore subclonal origin. 
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Figure S13 | Scatter plots of VAFs of SNVs from sorting replicates for patient 42. Nuclei were extracted, stained, and 
sorted on different days. Libraries were constructed and individually sequenced. The VAFs of SNVs from the first sort (x-
axis) are plotted versus the VAFs of SNVs from the second sort. 
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Figure S14 | Scatter plots of VAF of SNVs from sequencing replicates for patient 42. Libraries were constructed in 
duplicates and individually sequenced. The VAFs of SNVs from the first replicates (x-axis) are plotted versus the VAFs of 
SNVs from the second replicate. 
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Figure S15 | Regions of LOH in the primary tumor of patient 42. LOH in the three tumor populations from the primary 
tumor (2.1N, 3.4N, and 4.7N) and the metastasis (a). While the LOH of regions affected in all tumor populations (greenR2 
and pink) and LOH events that are shared among the 3.4N population, 4.7N population, and the metastasis affect the same 
chromosomes, the two LOH events that are shared between the 2.1N and 3.4N populations (blue, green region R4) affect 
the other homologous chromosome, respectively (c). The 4.7N population and the metastasis have the same breakpoint on 
chromosome 9p (in region R2) as the 2.1N population covering the CDKN2A locus (b), while this is absent in the 3.4N 
population. Many LOH events in the 3.4N population (chr13, chr14, chr15, chr18) and the LOH in the 2.1N population 
(chr17) are not present in the 4.7N population or in the metastasis.  
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Supplementary Tables  
Table S1 | Overview of the 409 genes that are included in the Ion Ampliseq™ Comprehensive Cancer Panel. The CCP 
panel covers all exons of these genes. 
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Table S2 | Overview of the 28 genes that are included in the Ion Ampliseq™ Custom Melanoma Panel. This panel covers 
all exons of these genes. 
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Appendix I – Array-CGH summary Part B 
Overview of genome-wide copy number aberrations of all 39 sorted tumors population from 37 
tumor samples of 16 patients with matched primary-metastatic LUAD. Shown are chromosome 1-
22 and the sex chromosomes X and Y. 
Blue: gain, red: deletion. Abbreviations: P: primary tumor, M: Metastasis, Δt: time between the 
occurrence of two tumors  
 
 
Note: Appendix I is divided into four parts 
 Patients 12, 20, 22, 31 | part 1  
 Patients 34, 35, 36, 38 | part 2 
 Patients 39, 41, 42, 44 | part 3 
 Patients 46, 48, 49, 50 | part 4 
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